Pyrazole-containing polycyclic derivative inhibitor as well as preparation method and application thereof
The P2X3 receptor inhibitor of the compound of formula (I) has been developed to solve the problems of major safety and side effects of existing drugs, providing an effective drug for the treatment of chronic cough and neurogenic diseases.
Patent Information
- Application Number
- CN202410932542.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-01
- Filing Date
- 2020-12-07
- Publication Date
- 2024-11-05
AI Technical Summary
The existing market lacks high safety and good non-addiction P2X3 receptor inhibitor drugs for the treatment of chronic cough and other diseases, and the drug has great side effects in existing clinical trials, which has failed to effectively reduce the frequency of cough.
Develop a compound of general formula (I) and its stereoisomers or pharmaceutically acceptable salts as a P2X3 receptor inhibitor, prepared by specific chemical structure and synthetic methods for the treatment of chronic cough and other neural sources Drugs for sexual diseases.
Provides a safe and effective P2X3 receptor inhibitor that is potentially used to treat chronic cough and other neurogenic diseases, reducing the side effects of the drug and improving the therapeutic effect.
Smart Images

Figure CN118894855A_ABST
Abstract
Description
[0001] This application is a divisional application of the PCT patent application entered into China with Chinese patent application number 2020800578212, invention name “Pyrazole polycyclic derivative inhibitors, preparation methods and applications thereof”, and application date December 7, 2020. Technical Field
[0002] The invention belongs to the field of drug synthesis, and specifically relates to an inhibitor containing pyrazole polycyclic derivatives, and a preparation method and application thereof. Background Art
[0003] P2X receptors, also known as P2X purinoreceptors, are a family of cation-permeable ATP ligand-gated ion channels that can bind to extracellular ATP. P2X receptors have seven subunits and exist in the form of homotrimers or heterotrimers. They are mainly expressed in nerve endings (presynaptic and postsynaptic) of the nervous system and regulate synaptic transmission. P2X3 receptors are members of the P2X family and are key sensory receptors for sensing upper respiratory tract stimuli and triggering cough reflexes. They are believed to play a key role in the sensitization of specific sensory nerves, participate in pain and cough, and participate in the perception of bone cancer pain. Blocking P2X3 can inhibit the signal stimulation of cough.
[0004] Cough is a defensive neural reflex of the body, which is beneficial for clearing respiratory secretions and harmful factors, but frequent and severe coughing can have a serious impact on the patient's work, life and social activities. Cough is divided into acute, subacute and chronic cough. Chronic cough refers to coughing for more than 8 weeks, with cough as the main or only symptom, and no obvious lesions in the lungs on chest imaging examination. Chronic cough has always been considered a consequence of various diseases, such as asthma / eosinophilic bronchitis, rhinitis and gastroesophageal reflux disease. However, recent evidence shows that chronic cough is a clinical symptom with unique intrinsic pathophysiological characteristics of neurosis. Unexplained chronic cough or idiopathic cough, this type of chronic irritating dry cough is the main manifestation, is sensitive to external stimuli, and is generally hypersensitive to cough. Hypersensitivity to cough is its physiological and pathological mechanism. Abnormalities in cough-related afferent nerves may be the cause of refractory or unexplained chronic cough. Chronic cough can cause complications in multiple systems such as cardiovascular, digestive, nervous, urinary, and musculoskeletal systems, such as urinary incontinence, syncope, insomnia, anxiety, etc.
[0005] Based on the pathophysiological characteristics of cough hypersensitivity syndrome, treatment should be aimed at reducing cough sensitivity. Currently, treatment options are limited, including drug treatment and non-drug treatment. Clinical research results show that the neuromodulator drug gabapentin is effective, and other drugs such as amitriptyline, baclofen, carbamazepine, and pregabalin can also be used. Severe cough can be treated with appropriate antitussive treatment. Antitussive drugs are mainly divided into central antitussives and peripheral antitussives. Central antitussive drugs are divided into dependent antitussives (morphine alkaloids and their derivatives) and non-dependent antitussives (synthetic dextromethorphan and pentoxyverine). The former has side effects such as addiction and narcotics, while the latter is widely used in clinical practice. Peripheral antitussives are also called terminal antitussives. They suppress coughs by inhibiting a certain link in the cough reflex arc, including local anesthetics (noscapine, benzonatate) and mucosal protective agents (benproperine and moguisteine).
[0006] At present, there are no approved P2X3 receptor antagonist small molecule drugs on the market. The P2X3 receptor antagonist drugs currently in the clinical stage include Merck & Co's MK-7264, which is used to treat diseases such as chronic cough, pain and pulmonary fibrosis. It has low selectivity for P2X3 / P2X2 / 3 and good safety, but has side effects such as loss of taste. The current indication of chronic cough has entered the Phase III clinical study. Bellus Health's BLU5937 has high selectivity and did not show side effects such as loss of taste in Phase I clinical trials. On July 6, 2020, Bellus Health announced the main research results of the Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough: In the Phase II clinical study, the RELIEF trial did not achieve the statistical significance of the primary endpoint of placebo-adjusted reduction in cough frequency at any dose. In addition, Bayer's BAY-1817080 and BAY-1902607, Shionogi's S-600918, are currently in clinical phase I / II for the treatment of chronic cough. Therefore, there is an urgent need to develop safe, non-addictive, and highly selective P2X3 receptor inhibitors for the treatment of chronic cough and other diseases to meet the huge market demand. Summary of the invention
[0007] The object of the present invention is to provide a compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the compound represented by general formula (I) has the following structure:
[0008]
[0009] in:
[0010] L1 is selected from a bond, -(CH2) n1-, -(CH2) n1 C(O)(CR aa R bb ) n2 -, -(CH2) n1 C(O)NR aa (CH2) n2 -, -(CH2) n1 (CR aa R bb ) n2 -, -(CR aa R bb ) n1 O(CH2) n2 -, -(CH2) n1 O(CR aa R bb ) n2 -, -(CR aa R bb ) n1 S(CH2) n2 -, -(CH2) n1 S(CR aa R bb ) n2 -, -(CR aa R bb ) n1 (CH2) n2 NR cc -, -(CH2) n1 NR aa (CR bb R cc ) n2 -, -(CH2) n1 NR aa C(O)-, -(CH2) n1 P(O)R aa -, -(CH2) n1 S(O) n2 -, -(CH2) n1 S(O) n2 NR aa - or -(CH2) n1 NR aa S(O) n2 -;
[0011] R aa ~R cceach independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0012] Or, R aa ~R cc Any two of them are linked to form a cycloalkyl, heterocyclic, aryl or heteroaryl group, and the cycloalkyl, heterocyclic, aryl and heteroaryl groups may be further substituted;
[0013] L2 is selected from a bond, -(CH2) n3 -、-(CH2) n3 C(O)(CR dd R ee ) n4 -、-(CH2) n3 C(O)NR dd (CH2) n4 -、-(CH2) n3 (CR dd R ee ) n4 -、-(CR dd R ee ) n3 O(CH2) n4 -、-(CH2) n3 O(CR dd R ee ) n4 -、-(CR dd R ee ) n3 S(CH2) n4 -、-(CH2) n3 S(CR dd R ee ) n4 -、-(CR dd R ee ) n3 (CH2) n4 NR ff -、-(CH2) n3 NR dd (CR ee R ff ) n4 -、-(CH2) n3 NR dd C(O)-、-(CH2)n3 P(O)R dd -、-(CH2) n3 S(O) n4 -、-(CH2) n3 S(O) n4 NR dd -or-(CH2) n3 NR dd S(O) n4 -;
[0014] R dd ~R ff each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, arylaryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0015] Or, R dd ~R ff Any two of them are linked to form a cycloalkyl, heterocyclic, aryl or heteroaryl group, and the cycloalkyl, heterocyclic, aryl and heteroaryl groups may be further substituted;
[0016] Ring A is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0017] R1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, arylaryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0018] Ring B is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0019] R2 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, arylaryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0020] R3 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl may be further substituted;
[0021] R a is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -(CH2) n5 R gg 、-(CH2) n5 OR gg 、-(CH2) n5 C(O)OR gg 、-(CH2) n5 SR gg 、-(CH2) n5 NR gg C(O)(CH2) n6 R hh 、-(CH2) n5 NR gg C(O)OR hh 、-(CH2) n5 NR gg C(O)NR hh R ii 、-(CH2) n5 NR gg R hh 、-NR gg (CH2) n5 R hh 、-(CH2) n5 C(O)NR gg (CH2) n6 R hh 、-(CH2) n5 C(O)R gg 、-OC(R gg R hh ) n5 (CH2) n6 R ii 、-(CH2) n5 S(O) n6 R gg 、-(CH2) n5 NRgg S(O) n6 R hh 、-CH=CH(CH2) n5 R gg 、-CH=CH(CH2) n5 NR gg R hh 、-CH=CH(CH2) n5 NR gg C(O)R hh or -CH=CH(CH2) n5 NR gg C(O)NR hh R ii , the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may be further substituted;
[0022] R gg ~R ii each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0023] Or, R gg ~R ii Any two of them are linked to form a cycloalkyl, heterocyclic, aryl or heteroaryl group, and the cycloalkyl, heterocyclic, aryl and heteroaryl groups may be further substituted;
[0024] x is an integer from 0 to 6;
[0025] e is an integer from 0 to 6;
[0026] n1, n3, and n5 are each independently an integer from 0 to 3; and
[0027] n2, n4, and n6 are each independently an integer of 0-2.
[0028] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, is characterized in that L1 is selected from a bond, -(CH2) n1 -、-(CH2) n1 C(O)(CR aa R bb )n2 -,-(CH2) n1 C(O)NR aa (CH2) n2 -,-(CH2) n1 (CR aa R bb ) n2 -,-(CR aa R bb ) n1 O(CH2) n2 -,-(CH2) n1 O(CR aa R bb ) n2 -,-(CR aa R bb ) n1 S(CH2) n2 -,-(CH2) n1 S(CR aa R bb ) n2 -,-(CR aa R bb ) n1 (CH2) n2 NR cc -,-(CH2) n1 NR aa (CR bb R cc ) n2 -,-(CH2) n1 C(O)(CR aa R bb ) n2 -,-(CH2) n1 NR aa C(O)-,-(CH2) n1 P(O)R aa -,-(CH2) n1 S(O) n2 -,-(CH2) n1 S(O) n2 NR aa - or -(CH2) n1 NR aa S(O) n2 -;
[0029] Preferably a bond,-(CH2) n1 -,-(CH2) n1 O(CR aa R bb ) n2 -,-(CH2) n1 S(CRaa R bb ) n2 -、-(CH2) n1 C(O)-、-(CH2) n1 NR aa -、-(CH2) n1 S(O) n2 -、-(CH2) n1 C(O)NR aa -、-C(O)NR aa (CH2) n2 -or-(CH2) n1 NR aa C(O)-;
[0030] More preferably a bond, -NH-, -C(O)NHCH2- or -C(O)N(CH3)CH2-;
[0031] R aa ~R cc Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0032] Or, R aa ~R cc Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0033] n1 is an integer from 0 to 3; and
[0034] n2 is an integer from 0 to 2.
[0035] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, is characterized in that L1 is selected from a bond or -C(O)-.
[0036] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, is characterized in that L2 is selected from a bond, -(CH2) n3 -、-(CH2) n3 C(O)(CR dd R ee ) n4 -、-(CH2) n3 C(O)NR dd (CH2) n4 -、-(CH2) n3 (CR dd R ee ) n4-、-(CR dd R ee ) n3 O(CH2) n4 -、-(CH2) n3 O(CR dd R ee ) n4 -、-(CR dd R ee ) n3 S(CH2) n4 -、-(CH2) n3 S(CR dd R ee ) n4 -、-(CR dd R ee ) n3 (CH2) n4 NR ff -、-(CH2) n3 NR dd (CR ee R ff ) n4 -、-(CH2) n3 NR dd C(O)-、-(CH2) n3 P(O)R dd -、-(CH2) n3 S(O) n4 -、-(CH2) n3 S(O) n4 NR dd -or-(CH2) n3 NR dd S(O) n4 -;
[0037] Preferred is -(CH2) n3 -、-(CH2) n3 O-, -(CH2) n3 S-, -(CH2) n3 NR dd -、-(CH2) n3 C(O)NR dd -or-(CH2) n3 NR dd C(O)-;
[0038] More preferably -CH2C(O)NH-;
[0039] R dd ~R ff Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0040] Or, R dd ~R ff Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0041] n3 is an integer from 0 to 3; and
[0042] n4 is an integer from 0 to 2.
[0043] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, Ring A is selected from C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 6-10 Aryl or 5-10 membered heteroaryl; more preferably phenyl, oxadiazolyl or pyridinyl.
[0044] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl or 5-14 membered heteroaryloxy, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 Aryloxy, 5-14 membered heteroaryl and 5-14 membered heteroaryloxy, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl, 5-14 membered heteroaryloxy, -(CH2) m1 OR a 、-(CH2) m1 SR a 、-(CH2) m1 C(O)R a 、-(CH2) m1 NR a R b 、-(CH2) m1 C(O)NR a R b 、-(CH2) m1 NR a C(O)R b and -(CH2) m1 S(O) m2 R a is substituted by one or more substituents;
[0045] Preferred are hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, the C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10Aryl, 5-8 membered heteroaryl, -(CH2) m1 C(O)R a 、-(CH2) m1 NR a R b 、-(CH2) m1 C(O)NR a R b 、-(CH2) m1 NR a C(O)R b and -(CH2) m1 S(O) m2 R a is substituted by one or more substituents;
[0046] More preferably, hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 4-6 membered heterocyclic group containing 1-2 nitrogen atoms, phenyl or 5-7 membered heteroaryl containing 1-2 nitrogen atoms, optionally further substituted with halogen, amino, hydroxy, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl or C 1-4 substituted by one or more substituents in the alkoxy group;
[0047] More preferably, hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, trifluoromethyl, fluorine, chlorine, bromine, amino, isopropenyl, cyclopropyl, cyclopentyl, cyclopentenyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, phenyl, pyridinyl,
[0048] R a and R b Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0049] Or, R a and R b Link Form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0050] m1 is an integer from 0 to 3; and
[0051] m2 is an integer from 0 to 2.
[0052] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0053] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0054] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0055] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy yl, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
[0056] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0057] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0058] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0059] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy yl, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
[0060] In a further preferred embodiment of the present invention, the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, R a is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R gg 、-(CH2) n5 OR gg 、-(CH2) n5 C(O)OR gg 、-(CH2) n5 SR gg 、-(CH2) n5 NR gg C(O)(CH2) n6 R hh 、-(CH2) n5 NR gg C(O)OR hh 、-(CH2) n5 NRgg C(O)NR hh R ii 、-(CH2) n5 NR gg R hh 、-NR gg (CH2) n5 R hh 、-(CH2) n5 C(O)NR gg (CH2) n6 R hh 、-(CH2) n5 C(O)R gg or -OC(R gg R hh ) n5 (CH2) n6 R ii ;
[0061] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0062] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0063] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy cyclohexyl, cycloheptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooxypropyl, cyclobutyl, cyclooxypentyl, cyclohexyl, cycloheptyl, aziridine, azetidinyl, azetyl, azopentyl, azohexyl, azepanyl, thienyl, pyrrolyl, pyridinyl, pyranyl, piperazinyl, phenyl or naphthyl;
[0064] R gg ~R ii Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0065] Or, R gg ~R ii Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0066] n5 is an integer from 0 to 3; and
[0067] n6 is an integer from 0 to 2.
[0068] In a further preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, the ring B is as follows:
[0069]
[0070] in:
[0071] M1, M2, M3 and M4 are each independently selected from CR A1 、C(O),N,CR A1 R A2 or NR A3 ;
[0072] R A1 ~R A3each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0073] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0074] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl.
[0075] In a further preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, M1, M2, M3 and M4 are each independently CR A1 ;
[0076] R A1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0077] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy yl, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
[0078] In a further preferred embodiment of the present invention, in the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, at least one of M1, M2, M3 and M4 is N;
[0079] Preferably, M4 is N, and M1, M2 and M3 are each independently selected from CR A1 ;
[0080] Or, M1 is N, M2, M3 and M4 are each independently selected from CR A1 ;
[0081] R A1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0082] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy yl, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
[0083] In a further preferred embodiment of the present invention, the ring B is as follows:
[0084]
[0085] in:
[0086] M6, M7 and M8 are each independently selected from CR A4 、C(O),N,O,S,CR A4 R A5 or NR A6 ;
[0087] R A4 ~R A6 each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl or heteroaryloxy, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, heteroaryl and heteroaryloxy may be further substituted;
[0088] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0089] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl.
[0090] In a further preferred embodiment of the present invention, the B ring is selected from the following groups;
[0091]
[0092] In a further preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, is characterized in that ring A is selected from
[0093] M5 is selected from N or CR4; preferably N or CH;
[0094] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by one or more substituents of aryl and 5-12 membered heteroaryl;
[0095] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0096] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0097] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy yl, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
[0098] In a further preferred embodiment of the present invention, the general formula (I) is further shown as general formula (II):
[0099]
[0100] Here, e is an integer from 0 to 3.
[0101] In a further preferred embodiment of the present invention, the general formula (I) is further shown as general formula (III):
[0102]
[0103] in:
[0104] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0105] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0106] More preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0107] More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy cyclohexyl, cycloheptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooxypropyl, cyclobutyl, cyclooxypentyl, cyclohexyl, cycloheptyl, aziridine, azetidinyl, azetyl, azopentyl, azohexyl, azepanyl, thienyl, pyrrolyl, pyridinyl, pyranyl, piperazinyl, phenyl or naphthyl;
[0108] R b is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;
[0109] Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0110] More preferably, hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycidyl, glycidyl, glycidyl, glycidyl, glycidyl, glycidyl, glycidyl, glycidyl, aziridine, azetidinyl, azopentyl, azohexyl, azepanyl, thienyl, pyrrolyl, pyridyl, pyranyl, piperazinyl, phenyl, or naphthyl; and
[0111] y is an integer from 0 to 3.
[0112] In a further preferred embodiment of the present invention, in the compound represented by general formula (III), its stereoisomers or pharmaceutically acceptable salts thereof, L1 is a bond or -C(O)-.
[0113] In a further preferred embodiment of the present invention, the compound represented by general formula (III), its stereoisomer or a pharmaceutically acceptable salt thereof, R1 is selected from hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 4-6 membered heterocyclic group containing 1-2 nitrogen atoms, phenyl or 5-7 membered heteroaryl containing 1-2 nitrogen atoms, optionally further substituted with halogen, amino, hydroxy, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl or C 1-4 The alkoxy group is substituted by one or more substituents.
[0114] In a further preferred embodiment of the present invention, the general formula (I) is further shown as general formula (IV):
[0115]
[0116] in:
[0117] Ring C is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl or absent;
[0118] Preferred C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl;
[0119] More preferably C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms;
[0120] Further preferred are cyclopropyl, cyclopentyl, cyclopentenyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, phenyl or pyridinyl;
[0121] R c is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl, 5-14 membered heteroaryloxy, -(CH2) m3 OR c 、-(CH2) m3 SR c 、-(CH2) m3 C(O)R c 、-(CH2) m3 NR c R d 、-(CH2) m3 C(O)NR c R d 、-(CH2) m3 NR c C(O)R d or -(CH2) m3 S(O) m4 R c , the amino group, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 Aryloxy, 5-14 membered heteroaryl and 5-14 membered heteroaryloxy, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 substituted by one or more substituents selected from the group consisting of aryloxy, 5-14-membered heteroaryl and 5-14-membered heteroaryloxy;
[0122] Preferred are hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl, 5-8 membered heteroaryl, -(CH2) m3 OR c 、-(CH2) m3 SR c 、-(CH2) m3 C(O)R c 、-(CH2) m3 NR c R d 、-(CH2) m3 C(O)NR c R d or -(CH2) m3 NR c C(O)R d , the amino group, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-8 membered heteroaryl;
[0123] Further preferred are hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, trifluoromethyl, fluorine, chlorine, bromine, amino or -C(O)CHF2;
[0124] R c and R d Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0125] Or, R c and R d Link Form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl;
[0126] m3 is an integer from 0 to 3;
[0127] m4 is an integer from 0 to 2; and
[0128] z is an integer from 0 to 6.
[0129] In a further preferred embodiment of the present invention, the general formula (II) is further shown as general formula (V):
[0130]
[0131] in:
[0132] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by one or more substituents of aryl and 5-12 membered heteroaryl;
[0133] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14Aryl and 5-14 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by one or more substituents of aryl and 5-12 membered heteroaryl;
[0134] R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl; and
[0135] e is an integer from 0 to 3.
[0136] In a preferred embodiment of the present invention, R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C6-10 Aryl and 5-10 membered heteroaryl, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl and 5-10 membered heteroaryl;
[0137] In a further preferred embodiment of the present invention, the R1 is selected from the following groups:
[0138] -H, -NH2, -F, -Cl, -Br, -CH3, -CH2CH3, -CF3,
[0139] In a preferred embodiment of the present invention, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0140] In a further preferred embodiment of the present invention, said R2 is selected from hydrogen, amino, cyano, fluorine, chlorine, bromine, methyl, isopropyl, trifluoromethyl, methoxy, cyclopropyl or morpholinyl;
[0141] In a preferred embodiment of the present invention, R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-1. membered heteroaryl;
[0142] In a further preferred embodiment of the present invention, said R3 is selected from hydrogen or cyano; and
[0143] e is an integer from 0 to 3.
[0144] In a preferred embodiment of the present invention, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof are selected from the following compounds:
[0145]
[0146]
[0147]
[0148]
[0149]
[0150] The present invention further relates to a method for preparing a compound represented by general formula (III), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, characterized in that it comprises the following steps:
[0151]
[0152] The compound represented by the general formula (III-2) reacts with the compound represented by the general formula (III-3) to obtain the target compound represented by the general formula (III);
[0153] in:
[0154] X2 is halogen; preferably chlorine or bromine.
[0155] The present invention further relates to a method for preparing a compound represented by general formula (III), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0156]
[0157] The compound represented by the general formula (III-1) is condensed into a ring to obtain the compound represented by the general formula (III-2), and the compound represented by the general formula (III-2) reacts with the compound represented by the general formula (III-3) to obtain the target compound represented by the general formula (III);
[0158] in:
[0159] X1 is halogen; preferably chlorine or bromine;
[0160] X2 is halogen; preferably chlorine or bromine.
[0161] The present invention further relates to a method for preparing a compound represented by general formula (IV), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0162]
[0163] The compound represented by the general formula (IV-2) reacts with the compound represented by the general formula (III-3) to obtain the target compound represented by the general formula (IV);
[0164] in:
[0165] X2 is halogen; preferably chlorine or bromine.
[0166] The present invention further relates to a method for preparing a compound represented by general formula (IV), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0167]
[0168] The compound represented by the general formula (IV-1) is condensed into a ring to obtain the compound represented by the general formula (IV-2), and the compound represented by the general formula (IV-2) reacts with the compound represented by the general formula (III-3) to obtain the target compound represented by the general formula (IV);
[0169] in:
[0170] X2 is halogen; preferably chlorine or bromine;
[0171] X3 is halogen; preferably chlorine or bromine.
[0172] The present invention further relates to a method for preparing a compound represented by general formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, characterized in that it comprises the following steps:
[0173]
[0174] The compound represented by the general formula (V-2) reacts with the compound represented by the general formula (V-3) to obtain the target compound represented by the general formula (V);
[0175] in:
[0176] X5 is halogen; preferably chlorine or bromine.
[0177] The present invention further relates to a method for preparing a compound represented by general formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, characterized in that it comprises the following steps:
[0178]
[0179] The compound represented by the general formula (V-1) is condensed into a ring to obtain the compound represented by the general formula (V-2), and the compound represented by the general formula (V-2) reacts with the compound represented by the general formula (V-3) to obtain the target compound represented by the general formula (V);
[0180] in:
[0181] X4 is halogen; preferably chlorine or bromine;
[0182] X5 is halogen; preferably chlorine or bromine.
[0183] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of any compound of the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0184] The present invention further relates to the use of any compound of the general formula (I), its stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition in the preparation of P2X3 receptor inhibitor drugs.
[0185] The present invention further relates to the use of a compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a medicament for treating a neurogenic disease, wherein the neurogenic disease is selected from gynecological diseases, urinary tract disease states, respiratory disorders, pulmonary fibrosis or pain-related diseases or conditions, etc.
[0186] The present invention further relates to a method for preparing a compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating neurogenic diseases.
[0187] The present invention also relates to a method for preventing and / or treating pre-prepared neurogenic diseases, which comprises administering to a patient a therapeutically effective dose of a compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0188] The present invention also provides methods of using the compounds or pharmaceutical compositions of the present invention to treat disease conditions, including but not limited to conditions associated with P2X3 receptor dysfunction.
[0189] The present invention also relates to a method for treating a neurogenic disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
[0190] In some embodiments, the methods are directed to diseases or conditions such as gynecological diseases, urinary tract disease states, respiratory disorders, or pain-related diseases or conditions.
[0191] In some embodiments, the methods relate to the treatment of conditions such as endometriosis, overactive bladder, pulmonary fibrosis, or chronic cough.
[0192] In some embodiments, the methods relate to neuropathic pain or pain and discomfort associated with uterine fibroids.
[0193] Chronic cough and neuropathic pain are preferred;
[0194] Chronic cough is more preferred.
[0195] Detailed description of the invention
[0196] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0197] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups. Methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl are preferred in the present invention.
[0198] The term "alkylene" refers to an alkyl group with one hydrogen atom further substituted, for example: "methylene" refers to -CH2-, "ethylene" refers to -(CH2)2-, "propylene" refers to -(CH2)3-, "butylene" refers to -(CH2)4-, etc. The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, for example, vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0199] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include cycloalkyls of spiro rings, fused rings and bridged rings, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
[0200] The term "spirocycloalkyl" refers to a polycyclic group that shares a carbon atom (called a spiral atom) between 5 to 20 monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiral atoms shared between rings, the spirocycloalkyl is divided into a single spiral cycloalkyl, a double spiral cycloalkyl or a multi-spirocycloalkyl, preferably a single spiral cycloalkyl and a double spiral cycloalkyl. More preferably, it is 3 yuan / 6 yuan, 3 yuan / 5 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral cycloalkyl. Non-limiting examples of spirocycloalkyl include:
[0201] .wait;
[0202] It also includes spirocycloalkyl groups that share a spiro atom with a heterocycloalkyl group. Non-limiting examples include:
[0203] wait.
[0204] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of condensed cycloalkyls include:
[0205] wait.
[0206] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:
[0207]
[0208] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0209] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O). m (wherein m is an integer from 0 to 2) heteroatoms, but excluding the ring part of -OO-, -OS- or -SS-, the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms; most preferably, it contains 3 to 8 ring atoms; further preferably, it contains 1-3 nitrogen atoms, 3-8 membered heterocyclic groups, optionally substituted by 1-2 oxygen atoms, sulfur atoms, oxo groups, including nitrogen-containing monocyclic heterocyclic groups, nitrogen-containing spiro heterocyclic groups or nitrogen-containing fused heterocyclic groups.
[0210] Non-limiting examples of monocyclic heterocyclic groups include oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azepanyl, 1,4-diazepanyl, pyranyl or tetrahydrothiopyran dioxide, and the like, preferably oxetanyl, thietanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azepanyl, 1,4-diazepanyl, pyranyl or tetrahydrothiopyran dioxide. The polycyclic heterocyclic groups include spirocyclic, condensed and bridged heterocyclic groups; the spirocyclic, condensed and bridged heterocyclic groups involved are optionally connected to other groups through single bonds, or further connected to other cycloalkyl, heterocyclic, aryl and heteroaryl groups through any two or more atoms on the ring.
[0211] The term "spiro heterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, spiral heterocyclic groups are divided into single spiral heterocyclic groups, double spiral heterocyclic groups or multi-spiro heterocyclic groups, preferably single spiral heterocyclic groups and double spiral heterocyclic groups. More preferably, it is 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic groups. Non-limiting examples of spiral heterocyclic groups include:
[0212] wait.
[0213] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:
[0214]
[0215] wait.
[0216] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
[0217]
[0218] wait.
[0219] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:
[0220] wait.
[0221] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0222] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, including benzo 5-10-membered heteroaryl, benzo 3-8-membered cycloalkyl and benzo 3-8-membered heteroalkyl, preferably benzo 5-6-membered heteroaryl, benzo 3-6-membered cycloalkyl and benzo 3-6-membered heteroalkyl, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen atoms, oxygen atoms, and sulfur atoms; or further comprising a three-membered nitrogen-containing fused ring containing a benzene ring.
[0223] Wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
[0224]
[0225]
[0226] wait.
[0227] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0228] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5 to 12-membered, more preferably 5-membered or 6-membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyridazinyl, pyrazinyl, etc., preferably pyridyl, oxadiazolyl, triazolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, pyrimidinyl, furyl, thienyl, pyridazinyl, pyrazinyl or thiazolyl; more preferably pyridyl, furyl, thienyl, pyrimidinyl, oxazolyl, oxadiazolyl, pyrazolyl, pyrrolyl, thiazolyl, pyridazinyl, pyrazinyl and oxazolyl. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which include:
[0229]
[0230] wait.
[0231] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0232] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0233] The term "alkylthio" refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples of alkylthio include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and alkylthio may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0234] "Haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0235] "Haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0236] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
[0237] "Alkenyl" refers to a chain alkenyl group, also known as an alkene group, wherein the alkenyl group can be further substituted by other related groups, for example: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0238] "Alkynyl" refers to (CH≡C-), wherein the alkynyl can be further substituted by other related groups, for example: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0239] The term "alkenylcarbonyl" refers to -C(O)-(alkenyl), wherein the definition of alkenyl is as described above. Non-limiting examples of alkenylcarbonyl include: vinylcarbonyl, propenylcarbonyl, butenylcarbonyl. Alkenylcarbonyl can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0240] "Hydroxy" refers to an -OH group.
[0241] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0242] "Amino" refers to -NH2.
[0243] "Cyano" refers to -CN.
[0244] "Nitro" refers to -NO2.
[0245] "Carbonyl" refers to -C(O)-.
[0246] "Carboxy" refers to -C(O)OH.
[0247] "THF" refers to tetrahydrofuran.
[0248] "EtOAc" means ethyl acetate.
[0249] "MeOH" refers to methanol.
[0250] "DMF" refers to N,N-dimethylformamide.
[0251] "DIPEA" refers to diisopropylethylamine.
[0252] "TFA" refers to trifluoroacetic acid.
[0253] "MeCN" refers to acetylene.
[0254] "DMA" refers to N,N-dimethylacetamide.
[0255] "Et2O" refers to diethyl ether.
[0256] "DCE" refers to 1,2-dichloroethane.
[0257] "DIPEA" refers to N,N-diisopropylethylamine.
[0258] "NBS" refers to N-bromosuccinimide.
[0259] "NIS" refers to N-iodosuccinimide.
[0260] "Cbz-Cl" refers to benzyl chloroformate.
[0261] "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium.
[0262] "Dppf" refers to 1,1'-bis(diphenylphosphino)ferrocene.
[0263] "HATU" refers to 2-(7-oxybenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
[0264] "KHMDS" refers to potassium hexamethyldisilazide.
[0265] "LiHMDS" refers to lithium bistrimethylsilylamide.
[0266] "MeLi" refers to methyllithium.
[0267] "n-BuLi" refers to n-butyllithium.
[0268] "NaBH(OAc)3" refers to sodium triacetoxyborohydride.
[0269] Different expressions such as “X is selected from A, B, or C”, “X is selected from A, B and C”, “X is A, B or C”, “X is A, B and C” all express the same meaning, that is, X can be any one or more of A, B, C.
[0270] The hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
[0271] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0272] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.
[0273] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0274] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity. DETAILED DESCRIPTION
[0275] The present invention is further described below with reference to examples, but these examples are not intended to limit the scope of the present invention.
[0276] Example
[0277] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or / and liquid chromatography-mass spectrometry (LC-MS). The NMR chemical shift (δ) is given in parts per million (ppm). The NMR is measured using a Bruker AVANCE-400 nuclear magnetic spectrometer, and the measurement solvents are deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3), and the internal standard is tetramethylsilane (TMS).
[0278] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1200 Infinity Series mass spectrometer. HPLC was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C 18 150×4.6mm chromatographic column).
[0279] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0280] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by or according to methods known in the art.
[0281] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, the solvent is a dry solvent, and the reaction temperature is in degrees Celsius.
[0282] Example 1
[0283] 2-(2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0284]
[0285] Step 1: Preparation of N-(3-(tert-butyl)-1H-pyrazol-5-yl)-2-chloronicotinamide
[0286]
[0287] To a DMF (30 mL) solution of 2-chloronicotinic acid (1.57 g, 9.96 mmol) were added 3-(tert-butyl)-1H-pyrazole-5-amine (2.77 g, 19.93 mmol), DIPEA (6.2 g, 49.8 mmol) and HATU (5.4 g, 0.144 mmol) in sequence under ice bath conditions, and the mixture was stirred for 1 h after removing the ice bath. The mixture was prepared to obtain Example 1-1 (2.5 g, 90%).
[0288] MS m / z(ESI):279.7[M+H] + .
[0289] Step 2: Preparation of 2-(tert-butyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one
[0290]
[0291] Potassium carbonate (1.61 g, 11.66 mmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (150.9 mg, 1.35 mmol) were added to a solution of Example 1-1 (2.5 g, 8.97 mmol) in DMF (50 mL), and the reaction solution was stirred at room temperature for 16 hours. The mixture was prepared to obtain Example 1-2 (2.1 g, 97%).
[0292] MS m / z(ESI):279.7[M+H] + .
[0293] Step 3: Preparation of 2-(2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0294]
[0295] Potassium carbonate (4.28 g, 30.96 mmol) and Example 1-3 (4.33 g, 18.57 mmol) were added to a solution of Example 1-2 (1.5 g, 6.19 mmol) in DMF (30 mL) at room temperature. The mixture was heated to 80°C and stirred for 2 h. After cooling, water was added, the precipitate was filtered and washed with ethyl acetate, and purified to obtain Example 1 (656 mg, yield: 27%).
[0296] MS m / z(ESI):395.4[M+H] + .
[0297] 1H NMR(400MHz,DMSO-d6)δ11.01(s,1H),8.80–8.78(m,1H),8.47(d,J=7.6Hz,1H),8.30(d,J=2.8Hz,1H),8 .01–7.94(m,1H),7.73–7.66(m,1H),7.49(dd,J=8.0,4.8Hz,1H),6.34(s,1H),4.87(s,2H),1.26(s,9H).
[0298] Example 2
[0299] 2-(2-bromo-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridine-2-
[0300] 4-(2-Methyl)acetamide
[0301]
[0302] The synthesis of Example 2 was carried out by referring to the method of Example 1, except that 3-bromo-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (500 mg, 68% yield).
[0303] MS m / z(ESI):418.2[M+H] + .
[0304] 1 H NMR (400MHz, DMSO-d6) δ11.32(s,1H),9.85(d,J=7.6Hz,1H),8.74(d,J=6.4Hz,1H),8.40(d,J= 2.8Hz,1H),8.05-8.00(m,1H),7.78-7.73(m,1H),7.23-7.17(m,1H),6.31(s,1H),5.52(s,2H).
[0305] Example 3
[0306] N-(5-fluoropyridin-2-yl)-2-(2-methyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl)-
[0307] (5H)methyl)acetamide
[0308]
[0309] The synthesis of Example 3 was carried out by referring to the method of Example 1, except that 3-methyl-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (20 mg, 26% yield).
[0310] MS m / z(ESI):353.3[M+H] + .
[0311] Example 4
[0312] N-(5-fluoropyridin-2-yl)-2-(2-ethyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl)-
[0313] (5H)methyl)acetamide
[0314]
[0315] The synthesis of Example 4 was carried out by referring to the method of Example 1, except that 3-ethyl-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (15 mg, 36% yield).
[0316] MS m / z(ESI):367.4[M+H] + .
[0317] Example 5
[0318] N-(5-fluoropyridin-2-yl)-2-(2-isopropyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl)-
[0319] (5H)methyl)acetamide
[0320]
[0321] The synthesis of Example 5 was carried out by referring to the method of Example 1, except that 3-isopropyl-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (15 mg, 36% yield).
[0322] MS m / z(ESI):381.4[M+H] + .
[0323] Example 6
[0324] N-(5-fluoropyridin-2-yl)-2-(2-isopropenyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl)-
[0325] (5H)methyl)acetamide
[0326]
[0327] Example 2 (100 mg, 0.24 mmol), isopropenylboronic acid (41.2 mg, 0.48 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (19.2 mg, 0.024 mmol) and cesium carbonate (232.8 mg, 0.72 mmol) were stirred in dioxane (4 mL) and water (1 mL) at 100°C for 1 hour in a microwave. The reaction solution was spin-dried and purified by preparative liquid phase to obtain Example 6 (54 mg, yield 60%).
[0328] MS m / z(ESI):379.4[M+H] + .
[0329] Example 7
[0330] N-(5-fluoropyridin-2-yl)-2-(5-oxo-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine
[0331] -4(5H)-methyl)acetamide
[0332]
[0333] The synthesis of Example 7 was carried out by referring to the method of Example 1, except that 3-trifluoromethyl-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (15 mg, 36% yield).
[0334] MS m / z(ESI):407.3[M+H] + .
[0335] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.96(dd,J=8.0,1.6Hz,1H),8.65(dd,J=8.0,1.6Hz, 1H),8.37(d,J=3.2Hz,1H),8.07-8.02(m,1H),7.78-7.73(m,2H),7.05(s,1H),5.02(s,2H).
[0336] Example 8
[0337] 2-(2-amino-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridine-2-
[0338] 4-(2-Methyl)acetamide
[0339]
[0340] Step 1: Preparation of 5-oxo-4,5-dihydropyrazolo[1,5-a]pyridine[3,2-e]pyrimidine-2-carboxylic acid methyl
[0341]
[0342] The synthesis method of Example 8-1 was based on the synthesis method of Example 1-2, and 5-amino-1H-pyrazole-3-carboxylic acid methyl ester was used to replace 3-(tert-butyl)-1H-pyrazole-5-amine to obtain Example 8-1 (500 mg, 73%).
[0343] MS: m / z(ESI):245.2[M+H] + .
[0344] Step 2: Preparation of methyl 4-(2-((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-5-oxo-4,5-dihydropyrazolo[1,5-a]pyridine[3,2-e]pyrimidine-2-carboxylate
[0345]
[0346] The synthesis method of Example 8-2 was based on the synthesis method of Example 1, and Example 8-1 was used as the raw material to obtain the title compound Example 8-2 (500 mg, 51%).
[0347] MS m / z(ESI):397.3[M+H] + .
[0348] Step 3: Preparation of 4-(2-((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-5-oxo-4,5-dihydropyrazolo[1,5-a]pyridine[3,2-e]pyrimidine-2-carboxylic acid
[0349]
[0350] To a solution of Example 8-2 (490 mg, 1.24 mmol) in tetrahydrofuran (10 mL) was added a solution of LiOH (519 mg, 12.36 mmol) in water (2 mL) at room temperature. The mixture was stirred at room temperature for 3 h, then the pH was adjusted to about 3 with 1 M HCl, and concentrated to dryness to obtain Example 8-3 (470 mg, 99%).
[0351] MS m / z(ESI):383.3[M+H] + .
[0352] Step 4: Preparation of 2-(2-amino-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0353]
[0354] Amine was added to a solution of Example 8-3 (450 mg, 1.2 mmol) in 1,4-dioxane (10 mL), Et3N (33 μL, 0.24 mmol) and BOP reagent (598 mg, 1.35 mmol), and stirred at room temperature for 20 min. Sodium azide (160 mg, 2.46 mmol) and tetrabutylammonium bromide (786 mg, 2.46 mmol) were added, and stirring was continued for 1 hour. The reaction was then diluted with 1,4-dioxane (12 mL), 2M H2SO4 (4 mL) aqueous solution was added, and heated at 100°C for 2 h. The solvent was evaporated, and the residue was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and the solvent was evaporated. Column chromatography purification gave Example 8 (360 mg, 86%).
[0355] MS m / z(ESI):354.3[M+H] + .
[0356] Example 9
[0357] 2-(2-cyclopropyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-
[0358] 2-amino)acetamide
[0359]
[0360] The synthesis method of Example 9 was based on the synthesis method of Example 6, except that ethylene boronic acid was replaced with cyclopropylboronic acid to obtain the title compound Example 9 (8 mg, 51%).
[0361] MS m / z(ESI):378.4[M+H] + .
[0362] Example 10
[0363] 2-(2-cyclopentyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-
[0364] 2-amino)acetamide
[0365]
[0366] The synthesis method of Example 10 was based on the synthesis method of Example 1, except that 3-cyclopentyl-1H-pyrazole-5-amine was substituted for 3-bromo-1H-pyrazole-5-amine to obtain the title compound Example 10 (9 mg, 28%).
[0367] MS m / z(ESI):407.4[M+H] + .
[0368] Embodiment 11
[0369] 2-(2-Cyclopentenyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0370]
[0371] The synthesis method of Example 11 was based on the synthesis method of Example 6, except that cyclopenteneboronic acid was used instead of ethyleneboronic acid to obtain the title compound Example 11 (15 mg, 81%).
[0372] MS m / z(ESI):405.4[M+H] + .
[0373] Example 12
[0374] N-(5-fluoropyridin-2-yl)-2-(5-oxo-2-(tetrahydro-2H-thiopyran-4-yl)pyrazol[1,5-a]
[0375] Pyridinyl[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0376]
[0377] Step 1: Preparation of 2-(2-(3,6-dihydro-2H-thiopyran-4-yl)-5-oxopyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0378]
[0379] The synthesis method of Example 12-1 was based on the synthesis method of Example 6, except that (3,6-dihydro-2H-thiopyran-4-yl)boronic acid was used instead of ethyleneboronic acid to obtain the title compound Example 12-1 (20 mg, 81%).
[0380] MS m / z(ESI):437.5[M+H] + .
[0381] Step 2: Preparation of N-(5-fluoropyridin-2-yl)-2-(5-oxo-2-(tetrahydro-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0382]
[0383] Example 12-1 (20 mg, 0.045 mmol) was dissolved in methanol (1 mL), 10% wet palladium carbon (2 mg) was added, and the mixture was heated to reflux under hydrogen. After the reaction was completed, the mixture was filtered through celite and purified to obtain Example 12 (13 mg, 65%).
[0384] MS m / z(ESI):439.5[M+H] + .
[0385] Embodiment 13
[0386] 2-(2-(2,2-difluoroacetyl)piperidin-4-yl)-5-oxopyrazolin[1,5-a]pyridin[3,2-e]pyrimidine-4-yl
[0387] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0388]
[0389] The synthesis method of Example 13 was followed by reference to the synthesis method of Example 6 to obtain the title compound Example 13 (6 mg, 11%).
[0390] MS m / z(ESI):500.4[M+H] + .
[0391] Embodiment 14
[0392] N-(5-fluoropyridin-2-yl)-2-(2-(oxetan-3-ylamino)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0393]
[0394] Example 9 (35.3 mg, 0.1 mmol) and oxetane (7.1 mg, 0.1 mmol) were dissolved in methanol (1 mL). Sodium borohydride (3.8 mg, 0.1 mmol) and p-toluenesulfonic acid monohydrate (0.1 mmol) were added to the resulting mixture, and the reaction solution was heated under reflux for 3 hours. The reaction mixture was quenched with saturated NaHCO3 aqueous solution (10 mL) and extracted with dichloromethane (3*10 mL). The mixed extracts were dried over anhydrous sodium sulfate, filtered and concentrated. The resulting crude product was purified to give Example 14 (20 mg, 50%).
[0395] MS m / z(ESI):410.4[M+H] + .
[0396] Embodiment 15
[0397] 2-(2-(Cyclopentylamino)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-
[0398] (2-fluoropyridin-2-yl)acetamide
[0399]
[0400] The synthesis method of Example 15 was followed by referring to the synthesis method of Example 14 to obtain the title compound Example 15 (7 mg, 13%).
[0401] MS m / z(ESI):422.4[M+H] + .
[0402] Example 16
[0403] N-(Cyclopropylmethyl)-4-(2-((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-N-methyl-5-oxo
[0404] -4,5-dihydropyrazolin[1,5-a]pyridin[3,2-e]pyrimidine-2-carboxamide
[0405]
[0406] Under ice bath, Example 8-3 (36.7 mg, 0.096 mmol) was dissolved in DMF (1 mL), 1-cyclopropyl-N-methylformamide (16.4 mg, 0.192 mmol), DIPEA (62 mg, 0.48 mmol) and HATU (54 mg, 0.144 mmol) were added in sequence, and the mixture was stirred for 1 h after removing the ice bath. The mixture was prepared to give Example 16 (22 mg, yield: 50%).
[0407] MS m / z(ESI):450.5[M+H] + .
[0408] Embodiment 17
[0409] N-(Cyclopropyl)-4-(2-((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-N-methyl-5-oxo-4,5-
[0410] Dihydropyrazolin[1,5-a]pyridin[3,2-e]pyrimidine-2-carboxamide
[0411]
[0412] The synthesis method of Example 17 was followed by referring to the synthesis method of Example 16 to obtain the title compound Example 17 (20 mg, 50%).
[0413] MS m / z(ESI):436.4[M+H] + .
[0414] Embodiment 18
[0415] N-(5-fluoropyridin-2-yl)-2-(5-oxo-2-phenylpyrazolin[1,5-a]pyridin[3,2-e]pyrimidine-4
[0416] (5H)-methyl)acetamide
[0417]
[0418] The synthesis method of Example 18 was followed by referring to the synthesis method of Example 6 to obtain the title compound Example 18 (6 mg, 54%).
[0419] MS m / z(ESI):415.4[M+H] + .
[0420] Embodiment 19
[0421] N-(5-fluoropyridin-2-yl)-2-(2-(6-methylpyridin-3-yl)-5-oxopyrazolin[1,5-a]pyridine
[0422] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0423]
[0424] The synthesis method of Example 19 was followed by referring to the synthesis method of Example 6 to obtain the title compound Example 19 (9 mg, 50%).
[0425] MS m / z(ESI):430.4[M+H] + .
[0426] Embodiment 20
[0427] N-(5-fluoropyridin-2-yl)-2-(2-(2-methylpyridin-4-yl)-5-oxopyrazolin[1,5-a]pyridine
[0428] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0429]
[0430] The synthesis method of Example 20 was followed by referring to the synthesis method of Example 6 to obtain the title compound Example 20 (13 mg, 50%).
[0431] MS m / z(ESI):430.4[M+H] + .
[0432] Embodiment 21
[0433] 2-(2,5-dimethylpyridin-4-yl)-5-oxopyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)
[0434] -N-(5-fluoropyridin-2-yl)acetamide
[0435]
[0436] The synthesis method of Example 21 was followed by referring to the synthesis method of Example 6 to obtain the title compound Example 21 (18 mg, 56%).
[0437] MS m / z(ESI):444.4[M+H] + .
[0438] 1 H NMR(400MHz,DMSO-d6)δ11.21(s,1H),8.90-8.86(m,1H),8.84-8.81(m,1H),8.76-8.74(m,1H),8.38(s,1H),8.30(s ,1H),8.06-7.98(m,1H),7.78-7.70(m,1H),7.53-7.47(m,1H),7.35(s,1H),5.44(s,2H),2.78(s,3H),2.74(s,3H).
[0439] Embodiment 22
[0440] 2-(2-(tert-butyl)-8-chloro-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0441] (5-Fluoropyridin-2-yl)acetamide
[0442]
[0443] The synthesis method of Example 22 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 22 (4 mg, 19%).
[0444] MS m / z(ESI):429.8[M+H] + .
[0445] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.52(d,J=8.4Hz,1H),8.38(d,J=2.8Hz,1H),8.08-8. 03(m,1H),7.79-7.74(m,1H),7.62(d,J=8.4Hz,1H),6.47(s,1H),4.93(s,2H),1.33(s,9H).
[0446] Embodiment 23
[0447] 2-(2-(tert-butyl)-8-methyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0448] (5-Fluoropyridin-2-yl)acetamide
[0449]
[0450] The synthesis method of Example 23 was based on the synthesis method of Example 1 to obtain the title compound Example 23 (8 mg, 19%).
[0451] MS m / z(ESI):409.4[M+H] + .
[0452] 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.40(d,J=8.0Hz,1H),8.37(d,J=3.2Hz,1H),8.06-8.02(m,1H), 7.75(td,J=8.4,2.8Hz,1H),7.42(d,J=8.0Hz,1H),6.38(s,1H),4.93(s,2H),2.68(s,3H),1.33(s,9H).
[0453] Embodiment 24
[0454] 2-(2-(tert-butyl)-7-methyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0455] (5-Fluoropyridin-2-yl)acetamide
[0456]
[0457] The synthesis method of Example 24 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 24 (7 mg, 16%).
[0458] MS m / z(ESI):409.4[M+H] + .
[0459] 1 H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.70(d,J=2.3Hz,1H),8.36(dd,J=8.7,2.7Hz,2H),8. 04(s,1H),7.76(dt,J=8.9,4.5Hz,1H),6.38(s,1H),4.93(s,2H),2.45(s,3H),1.31(s,9H).
[0460] Embodiment 25
[0461] 2-(2-(tert-butyl)-6-methyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0462] (5-Fluoropyridin-2-yl)acetamide
[0463]
[0464] The synthesis method of Example 25 was based on the synthesis method of Example 1 to obtain the title compound Example 25 (5 mg, 16%).
[0465] MS m / z(ESI):409.4[M+H] + .
[0466] Embodiment 26
[0467] 2-(2-(tert-butyl)-5-oxopyrazolin[1,5-a]quinazolin-4(5H)-yl)-N-(5-fluoropyridine-2-yl)
[0468] 4-(2-Methyl)acetamide
[0469]
[0470] The synthesis method of Example 26 was based on the synthesis method of Example 1 to obtain the title compound Example 26 (6 mg, 16%).
[0471] MS m / z(ESI):394.4[M+H] + .
[0472] Embodiment 27
[0473] 2-(2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[2,3-e]pyrimidin-4(5H)-yl)-N-(5-
[0474] (2-fluoropyridin-2-yl)acetamide
[0475]
[0476] The synthesis method of Example 27 was based on the synthesis method of Example 1 to obtain the title compound Example 27 (6 mg, 16%).
[0477] MS m / z(ESI):395.4[M+H] + .
[0478] Embodiment 28
[0479] 2-(2-(tert-butyl)-7-methyl-5-oxopyrazolo[1,5-a]pyridin[2,3-e]pyrimidin-4(5H)-yl)-N-
[0480] (5-Fluoropyridin-2-yl)acetamide
[0481]
[0482] The synthesis method of Example 28 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 28 (9 mg, 21%).
[0483] MS m / z(ESI):409.4[M+H] + .
[0484] Embodiment 29
[0485] 2-(2-(tert-butyl)-7-chloro-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0486] (5-Fluoropyridin-2-yl)acetamide
[0487]
[0488] The synthesis method of Example 29 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 29 (15 mg, 32%).
[0489] MS m / z(ESI):429.1[M+H] + .
[0490] 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.91(d,J=2.4,1H),8.54(d,J=2.4Hz,1H),8.38(d,J =2.8Hz,1H),8.08-8.02(m,1H),7.79-7.74(m,1H),6.47(s,1H),4.94(s,2H),1.32(s,9H).
[0491] Embodiment 30
[0492] 2-(2-(tert-butyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl
[0493] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0494]
[0495] The synthesis method of Example 30 was based on the synthesis method of Example 1, and 2-chloro-6-trifluoromethylnicotinic acid was used as the raw material to obtain the title compound Example 30 (25 mg, 46%).
[0496] MS m / z(ESI):463.1[M+H] + .
[0497] 1 H NMR (400MHz, DMSO-d6) δ11.09(s,1H),7.78(d,J=8.0Hz,1H),8.38(d,J=2.8Hz,1H),8.09-8. 04(m,1H),8.00(d,J=8.0Hz,1H),7.79-7.74(m,1H),6.52(s,1H),4.95(s,2H),1.34(s,9H).
[0498] Embodiment 31
[0499] 2-(tert-Butyl)-4-(4-chlorobenzyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one
[0500]
[0501] The synthesis method of Example 31 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 31 (12 mg, 24%).
[0502] MS m / z(ESI):367.1[M+H] + .
[0503] 1 H NMR (400MHz, DMSO-d6) δ8.83 (dd, J=4.8, 1.6Hz, 1H), 8.56 (dd, J=8.0, 1.6Hz, 1H), 7.55 (dd, J=8.0 ,4.8Hz,1H),7.45(d,J=8.4Hz,1H),7.39(d,J=8.4Hz,1H),6.31(s,1H),5.25(s,2H),1.30(s,9H).
[0504] Embodiment 32
[0505] 2-(2-(tert-butyl)-7-isopropyl-5,8-dioxo-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]pyrrolo
[0506] [3,4-e]pyrimidin-4-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0507]
[0508] Step 1: Preparation of 4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid
[0509]
[0510] LiOH (0.23 g, 9.4 mmol) was added to a solution of Example 32-1 (2.0 g, 9.4 mmol) in CH3OH (30 mL) under ice bath conditions, and the ice bath was removed and stirred for 1 h. The reaction solution was adjusted to pH 5-6 with 1 mol / L aqueous hydrochloric acid solution, extracted with ethyl acetate (10 mL*3), and the organic phase was dried and concentrated to obtain Example 32-2 (1.5 g, 73%).
[0511] MS m / z(ESI):184.7[MH] + .
[0512] Step 2: Preparation of N-(3-(tert-butyl)-1H-pyrazol-5-yl)-4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide
[0513]
[0514] The synthesis method of Example 32-3 was based on the synthesis method of Example 1-1, and Example 32-2 was used as the raw material to obtain the title compound Example 32-3 (0.26 g, 44%).
[0515] MS m / z(ESI):307.2[M+H] + .
[0516] Step 3: Preparation of 2-(tert-butyl)-7-isopropyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidine-5,8-dione
[0517]
[0518] The synthesis method of Example 32-4 was based on the synthesis method of Example 1-2, and Example 32-3 was used as the raw material to obtain the title compound Example 32-4 (0.18 g, 78%).
[0519] MS m / z(ESI):289.2[M+H] + .
[0520] Step 4: Preparation of 2-(2-(tert-butyl)-7-isopropyl-5,8-dioxo-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-4-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0521]
[0522] The synthesis method of Example 32-4 was based on the synthesis method of Example 1, and Example 32-4 was used as the raw material to obtain the title compound Example 32-5 (0.12 g, 65%).
[0523] MS m / z(ESI):441.2[M+H] + .
[0524] Embodiment 33
[0525] N-(5-fluoropyridin-2-yl)-2-(2-methyl-5-oxo-8-(trifluoromethyl)pyrazolin[1,5-a]pyridine
[0526] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0527]
[0528] The synthesis method of Example 33 was carried out by referring to the synthesis method of Example 2 to obtain the title compound Example 33 (18 mg, 30%).
[0529] MS m / z(ESI):421.1[M+H] + .
[0530] 1H NMR(400MHz,DMSO-d6)δ11.06(s,1H),8.80(d,J=8.0Hz,1H),8.37(s,1H),8.07-8.03(m ,1H),8.00(d,J=8.0Hz,1H),7.79-7.73(m,1H),6.28(s,1H),4.95(s,2H),2.33(s,3H).
[0531] Embodiment 34
[0532] 2-(2-ethyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0533] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0534]
[0535] Step 1: Preparation of tert-butyl 5-amino-3-ethyl-1H-pyrazole-1-carboxylate
[0536]
[0537] 3-Ethyl-1H-pyrazol-5-amine (2.0 g, 18.0 mmol) was dissolved in anhydrous dichloromethane (50 mL), triethylamine (2.2 g, 21.6 mmol) and di-tert-butyl dicarbonate (4.7 g, 21.6 mmol) were added, and the mixture was reacted at room temperature for 16 hours. The reaction solution was washed with water (50 mL*2) and saturated sodium chloride solution (50 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to column chromatography (ethyl acetate / dichloromethane = 0-20%) to obtain the title product Example 34-1 (3.4 g), with a yield of 89.5%.
[0538] MS:m / z(ESI):212.1[M+H] + .
[0539] Step 2: Preparation of tert-butyl 5-amino-3-ethyl-1H-pyrazole-1-carboxylate
[0540]
[0541] Example 34-1 (3.4 g, 16.1 mmol) was dissolved in anhydrous dichloromethane (60 mL), triethylamine (5.4 g, 53.1 mmol) was added, and a dichloromethane solution (50 mL) of 2-chloro-6-trifluoromethylnicotinic acid chloride (4.3 g, 17.7 mmol) prepared was added dropwise at 0°C under nitrogen protection, and the mixture was reacted at room temperature for 30 minutes. The reaction solution was washed with water (200 mL*2) and saturated sodium chloride solution (200 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was chromatographed on a silica gel column (ethyl acetate / petroleum ether = 0-20%) to obtain Example 34-2 (2.6 g), with a yield of 38.2%.
[0542] MS:m / z(ESI):319.1[M-Boc+H] + .
[0543] Step 3: Preparation of N-(3-ethyl-1H-pyrazol-5-yl)-2-chloro-6-(trifluoromethyl)nicotinamide
[0544]
[0545] Example 34-2 (2.6 g, 6.2 mmol) was dissolved in anhydrous dichloromethane (10 mL), and dioxane hydrochloride solution (4 M, 20 mL) was added, and the mixture was reacted at room temperature for 4 hours. The reaction solution was directly spin-dried to obtain Example 34-3 (1.9 g), with a yield of 96.0%.
[0546] MS:m / z(ESI):319.0[M+H] + .
[0547] Step 4: 2-ethyl-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one
[0548]
[0549] Example 34-3 (1.9 g, 6.0 mmol) was dissolved in N,N-dimethylformamide (20 mL), potassium carbonate (2.5 g, 18.0 mmol) was added, and the mixture was heated to 120° C. for 2 hours. The reaction solution was cooled to room temperature and used directly in the next step.
[0550] MS:m / z(ESI):283.1[M+H] + .
[0551] Step 5: 2-(2-ethyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0552]
[0553] Potassium carbonate (1.5 g, 10.6 mmol) and 2-bromo-N-(5-fluoropyridin-2-yl)acetamide (0.99 g, 4.2 mmol) were added to the reaction solution of Example 34-4 (1.0 g, 3.5 mmol) in N, N-dimethylformamide (20 mL), and the mixture was reacted at 40°C for 2 hours. The reaction solution was cooled to room temperature, poured into 300 mL of water, and extracted with ethyl acetate (200 mL*3). The organic phases were combined, washed with water (200 mL*2) and saturated sodium chloride solution (200 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from ethyl acetate to obtain Example 34.
[0554] 1 H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.79(d,J=7.6Hz,1H),8.37(s,1H),8.07–8.03(m,1H),8.00(d,J =8.0Hz,1H),7.79–7.72(m,1H),6.36(s,1H),4.96(s,2H),2.70(q,J=7.6Hz,2H),1.25(t,J=7.6Hz,3H).
[0555] MS m / z(ESI):435.1[M+H] + .
[0556] Embodiment 35
[0557] 2-(2-cyclopropyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0558] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0559]
[0560] The synthesis method of Example 35 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 35 (17 mg, 28%).
[0561] 1H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.78(d,J=8.0Hz,1H),8.37(s,1H),8.08–8.02(m,1H),7.98(d,J=8.4H z,1H),7.79-7.73(m,1H),6.23(s,1H),4.91(s,2H),2.11–2.04(m,1H),1.04-0.98(m,2H),0.82–0.78(m,2H).
[0562] MS m / z(ESI):447.1[M+H] + .
[0563] Embodiment 36
[0564] N-(5-fluoropyridin-2-yl)-2-(2-isopropyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridine
[0565] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0566]
[0567] The synthesis method of Example 36 was followed by referring to the synthesis method of Example 4 to obtain the title compound Example 36 (10 mg, 22%).
[0568] MS m / z(ESI):449.1[M+H] + .
[0569] 1 H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.79(d,J=8.0Hz,1H),8.37(s,1H),8.09-8.03(m,1H),8.00(d,J =8.0Hz,1H),7.79-7.74(m,1H),6.42(s,1H),4.96(s,2H),3.08-3.01(m,1H),1.29(s,3H),1.27(s,3H).
[0570] Embodiment 37
[0571] 2-(2-cyclopentyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0572] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0573]
[0574] The synthesis method of Example 37 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 37 (18 mg, 30%).
[0575] MS m / z(ESI):475.1[M+H] + .
[0576] 1 H NMR(400MHz,DMSO)δ11.07(s,1H),8.79(d,J=8.0Hz,1H),8.38(s,1H),8.14–7.89(m,2H ),7.77(s,1H),6.42(s,1H),4.96(s,2H),3.17(s,1H),2.14–1.93(m,3H),1.67(m,5H).
[0577] Embodiment 38
[0578] 2-(2-(4,4-difluorocyclohexyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0579]
[0580] The synthesis method of Example 38 was based on the synthesis method of Example 1 to obtain the title compound Example 38 (8 mg, 20%).
[0581] MS m / z(ESI):525.1[M+H] + .
[0582] 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.79(d,J=8.2Hz,1H),8.37(d,J=3.0Hz,1H),8.01(d,J=8.0Hz,2H),7.76 (t,J=9.0Hz,1H),6.49(s,1H),4.95(s,2H),2.95(s,1H),2.05(q,J=19.1,17.8Hz,6H),1.74(d,J=13.1Hz,2H).
[0583] Embodiment 39
[0584] N-(5-fluoropyridin-2-yl)-2-(2-(6-methylpyridin-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0585]
[0586] The synthesis method of Example 39 was followed by referring to the synthesis method of Example 1 to obtain the title compound Example 39 (15 mg, 28%).
[0587] MS m / z(ESI):498.1[M+H] + .
[0588] 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),9.01(s,1H),8.85(d,J=8.0Hz,1H),8.37(d,J=2.8Hz,1H),8.25(dd,J=8.0 ,2.4Hz,1H),8.13–8.03(m,2H),7.79-7.74(m,1H),7.41(d,J=8.0Hz,1H),7.15(s,1H),5.02(s,2H),2.54(s,3H).
[0589] Embodiment 40
[0590] 2-(2,5-dimethylpyridin-4-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0591]
[0592] The synthesis method of Example 40 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 40 (22 mg, 45%).
[0593] MS m / z(ESI):512.1[M+H] + .
[0594] 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 8.86 (d, J = 8.4Hz, 1H), 8.46–8.43 (m, 2H), 8.39–8.36 (m, 1H), 8. 12–8.03(m,2H),7.79–7.74(m,1H),7.57(s,1H),7.02(s,1H),5.05(s,2H),2.53(s,3H),2.51(s,3H).
[0595] Embodiment 41
[0596] 2-(2-amino-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0597] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0598]
[0599] The synthesis method of Example 41 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 41 (12 mg, 26%).
[0600] MS m / z(ESI):422.1[M+H] + .
[0601] Embodiment 42
[0602] 2-(2-(Cyclopentylamino)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl)-
[0603] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0604]
[0605] The synthesis method of Example 42 was followed by referring to the synthesis method of Example 8 to obtain the title compound Example 42 (9 mg, 19%).
[0606] MS m / z(ESI):489.2[M+H] + .
[0607] Embodiment 43
[0608] N-(5-fluoropyridin-2-yl)-2-(2-(oxetan-3-ylamino)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0609]
[0610] The synthesis method of Example 43 was followed by referring to the synthesis method of Example 14 to obtain the title compound Example 43 (15 mg, 25%).
[0611] MS m / z(ESI):478.1[M+H] + .
[0612] Embodiment 44
[0613] 2-(8-amino-2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0614] (5-Fluoropyridin-2-yl)acetamide
[0615]
[0616] Step 1: Preparation of 2-(8-amino-2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0617]
[0618] At room temperature, Example 22 (100 mg, 0.234 mmol) and aqueous ammonia (5 mL) were added to a round-bottom flask, and the mixture was stirred at 80° C. for 5 h. After the reaction was completed, Example 44 (52 mg, 54%) was obtained by HPLC.
[0619] MS m / z(ESI):410.2[M+H] + .
[0620] 1 H NMR(400MHz,DMSO-d6)δ10.96(s,1H),8.41(s,1H),8.02-7.95(m,1H),7.93(d,J=8.8Hz,1H ),7.68(s,1H),7.45(s,2H),6.43(d,J=8.7Hz,1H),6.15(s,1H),4.79(s,2H),1.23(s,9H).
[0621] Embodiment 45
[0622] 2-(2-(tert-butyl)-8-cyano-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0623] (5-Fluoropyridin-2-yl)acetamide
[0624]
[0625] Step 1: Preparation of 2-(2-(tert-butyl)-8-cyano-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0626]
[0627] At room temperature, Example 22 (80 mg, 0.187 mmol), CuCN (45 mg, 0.5 mmol) and DMF (2 mL) were added to a round-bottom flask, and the mixture was stirred at 150° C. for 5 h under nitrogen protection. After the reaction was completed, Example 45 (26 mg, 33%) was obtained by HPLC.
[0628] MS m / z(ESI):420.1[M+H] + .
[0629] 1 H NMR (400MHz, DMSO) δ11.06 (s, 1H), 8.72 (d, J = 8.0Hz, 1H), 8.37 (s, 1H), 8.17 –7.98(m,2H),7.77(d,J=8.3Hz,1H),6.51(s,1H),4.94(s,2H),1.28(s,9H).
[0630] Embodiment 46
[0631] 2-(2-(tert-butyl)-8-methoxy-5-oxopyrazolin[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0632] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0633]
[0634] Step 1: Preparation of 2-(2-(tert-butyl)-8-methoxy-5-oxopyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0635]
[0636] At room temperature, Example 22 (80 mg, 0.187 mmol), MeONa (43 mg, 0.8 mmol) and DMF (2 mL) were added to a round-bottom flask, and the mixture was stirred at 80° C. for 3 h under nitrogen protection. After the reaction was completed, Example 46 (35 mg, 45%) was obtained by HPLC.
[0637] MS m / z(ESI):425.0[M+H] + .
[0638] 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),8.45(d,J=8.8Hz,1H),8.37(d,J=3.2Hz,1H),8.06-8.00(m, 1H),7.76-7.71(m,1H),6.75(d,J=8.8Hz,1H),6.55(s,1H),5.24(s,2H),3.88(s,3H),1.33(s,9H).
[0639] Embodiment 47
[0640] 2-(2-(tert-butyl)-5-oxo-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl
[0641] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0642]
[0643] The synthesis of Example 47 was carried out by referring to the method of Example 1, except that 2-chloro-5-(trifluoromethyl)nicotinic acid was used instead of 2-chloronicotinic acid to obtain Example 47 (36 mg, 52%).
[0644] MS m / z(ESI):463.1[M+H] + .
[0645] 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),9.24(s,1H),8.73(s,1H),8.36(d,J=3.1Hz,1H),8 .04(s,1H),7.75(td,J=8.8,3.2Hz,1H),6.51(d,J=2.7Hz,1H),4.96(s,2H),1.33(s,9H).
[0646] Embodiment 48
[0647] 2-(2-(tert-butyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl
[0648] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0649]
[0650] The synthesis of Example 48 was carried out by referring to the method of Example 1, except that 2,4-dichloronicotinic acid was used instead of 2-chloronicotinic acid to obtain Example 48 (52 mg, 46%).
[0651] MS m / z(ESI):429.2[M+H] + .
[0652] Embodiment 49
[0653] 2-(2-(tert-butyl)-6-isopropyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-
[0654] N-(5-Fluoropyridin-2-yl)acetamide
[0655]
[0656] Step 1: Preparation of 2-(2-(tert-butyl)-6-isopropyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0657]
[0658] Under nitrogen protection at -70°C, isopropylmagnesium bromide (1 M, 1 mL) was added dropwise to a solution of Example 48 (100 mg, 0.233 mmol) in THF (5 mL), and the mixture was stirred at room temperature for 3 h. After the reaction, Example 49 (62 mg, 60%) was obtained by HPLC.
[0659] MS m / z(ESI):437.0[M+H] + .
[0660] Embodiment 50
[0661] 2-(2-(tert-butyl)-6-cyclopropyl-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-
[0662] N-(5-Fluoropyridin-2-yl)acetamide
[0663]
[0664] Synthesis of Example 50 Referring to the method of Example 49, cyclopropylmagnesium bromide was used instead of isopropylmagnesium bromide to obtain Example 50 (36 mg, 58%).
[0665] MS m / z(ESI):435.2[M+H] + .
[0666] Embodiment 51
[0667] 2-(2-(tert-butyl)-5-oxo-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4-yl
[0668] (5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0669]
[0670] The synthesis of Example 51 was carried out by referring to the method of Example 1, except that 2-chloro-4-(trifluoromethyl)nicotinic acid was used instead of 2-chloronicotinic acid to obtain Example 51 (36 mg, 52%).
[0671] MS m / z(ESI):463.1[M+H]+ .
[0672] Embodiment 52
[0673] 2-(6-amino-2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-
[0674] (5-Fluoropyridin-2-yl)acetamide
[0675]
[0676] The synthesis of Example 52 was carried out by referring to the method of Example 44, and Example 22 was replaced by Example 48 to obtain Example 52 (36 mg, 52%).
[0677] MS m / z(ESI):410.2[M+H] + .
[0678] Embodiment 53
[0679] 2-(7-(tert-butyl)-4-oxopyrazolo[1,5-a]thiazo[5,4-e]pyrimidin-5(4H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0680]
[0681] The synthesis method of Example 53 was carried out by referring to the synthesis method of Example 1 to obtain the title compound (19 mg, 21%).
[0682] MS m / z(ESI):401.4[M+H] + .
[0683] Embodiment 54
[0684] 2-(7-(tert-butyl)-3-isopropyl-4-oxo-3,4-dihydro-5H-pyrazolo[5,1-b]purin-5-yl)-N-
[0685] (5-Fluoropyridin-2-yl)acetamide
[0686]
[0687] The synthesis method of Example 54 was carried out by referring to the synthesis method of Example 1 to obtain the title compound (11 mg, 28%).
[0688] MS m / z(ESI):426.5[M+H] + .
[0689] Embodiment 55
[0690] 2-(2-(tert-butyl)-6-ethyl-5-oxo-5,6-dihydro-4H-dipyrazolo[1,5-a:3',4'-e]pyrimidine-4-
[0691] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0692]
[0693] The synthesis method of Example 55 was carried out by referring to the synthesis method of Example 1 to obtain the title compound (26 mg, 28%).
[0694] MS m / z(ESI):412.4[M+H] + .
[0695] Embodiment 56
[0696] 2-(7-(tert-butyl)-3-methyl-4-oxoisoxazolo[4,3-e]pyrazolo[1,5-a]pyrimidin-5(4H)-yl)-
[0697] N-(5-Fluoropyridin-2-yl)acetamide
[0698]
[0699] The synthesis method of Example 56 was carried out by referring to the synthesis method of Example 1 to obtain the title compound (23 mg, 25%).
[0700] MS m / z(ESI):399.4[M+H] + .
[0701] Embodiment 57
[0702] 2-(7-(tert-butyl)-3-methyl-4-oxoisothiazo[4,3-e]pyrazolo[1,5-a]pyrimidin-5(4H)-yl)-
[0703] N-(5-Fluoropyridin-2-yl)acetamide
[0704]
[0705] The synthesis method of Example 57 was carried out by referring to the synthesis method of Example 1 to obtain the title compound (19 mg, 29%).
[0706] MS m / z(ESI):415.5[M+H] + .
[0707] Embodiment 58
[0708] 2-(2-(tert-butyl)-5-thiopyrazolo[1,5-a]pyridinyl[3,2-e]pyrimidin-4(5H)-yl)-N-
[0709] (5-Fluoropyridin-2-yl)acetamide
[0710]
[0711] Step 1: Preparation of 2-(2-(tert-butyl)-5-thiopyrazolo[1,5-a]pyridinyl[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0712]
[0713] To a toluene (2 mL) solution of Example 1 (50 mg, 0.13 mmol) was added Lawesson's reagent (158 mg, 0.39 mmol) at room temperature and heated in a microwave at 115°C for 1 hour. LCMS showed that the reaction was complete. p-HPLC (HCOOH) was used to obtain Example 58 (5 mg, 10%).
[0714] MS m / z(ESI):411.13[M+H] + .
[0715] Embodiment 59
[0716] N-(5-fluoropyridin-2-yl)-2-(2-(1-methylcyclopropyl)-5-oxo-8-(trifluoromethyl)pyrazole
[0717] [1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0718]
[0719] The synthesis method of Example 59 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 59 (21 mg, 40%).
[0720] MS m / z(ESI):461.4[M+H] + .
[0721] 1 H NMR(400MHz,DMSO)δ11.04(s,1H),8.78(d,J=7.6Hz,1H),8.37(s,1H),8.17–7.90(m,2H) ,7.76(t,J=8.1Hz,1H),6.35(s,1H),4.93(s,2H),1.47(s,3H),1.03(s,2H),0.85(s,2H).
[0722] Embodiment 60
[0723] N-(5-fluoropyridin-2-yl)-2-(5-oxo-8-(trifluoromethyl)-2-(1-(trifluoromethyl)cyclopropyl)pyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0724]
[0725] The synthesis method of Example 60 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 60 (15 mg, 31%).
[0726] MS m / z(ESI):515.4[M+H] + .
[0727] Embodiment 61
[0728] 2-(2-(2,2-difluoroethyl)azepin-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0729]
[0730] Step 1: Preparation of tert-butyl 5-amino-3-bromo-1H-pyrazole-1-carboxylate
[0731]
[0732] 3-Bromo-1H-pyrazole-5-amine (10.0 g, 61.7 mmol) was dissolved in anhydrous dichloromethane (100 mL), triethylamine (7.48 g, 74.1 mmol) and di-tert-butyl dicarbonate (16.0 g, 74.1 mmol) were added, and the mixture was reacted at room temperature for 16 hours. The reaction solution was washed with water (50 mL*2) and saturated sodium chloride solution (50 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to column chromatography (ethyl acetate / dichloromethane = 0-20%) to obtain the title product 5-amino-3-bromo-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 61-1 (14.5 g), with a yield of 89.5%.
[0733] MS:m / z(ESI):262.0[M+H] +
[0734] 1 H NMR (400MHz, DMSO-d6) δ6.62(s,2H),5.41(s,1H),1.56(s,9H).
[0735] Step 2: Preparation of tert-butyl 5-amino-3-bromo-1H-pyrazole-1-carboxylate
[0736]
[0737] Dissolve 5-amino-3-bromo-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 61-1 (14.5 g, 55.3 mmol) in anhydrous dichloromethane (200 mL), add triethylamine (18.5 g, 183 mmol), and add the prepared 2-chloro-6-trifluoromethylnicotinic acid chloride (13.0 g, 61.0 mmol) in dichloromethane (50 mL) dropwise at 0°C under nitrogen protection, and react at room temperature for 30 minutes. The reaction solution is washed with water (200 mL*2) and saturated sodium chloride solution (200 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained crude product is chromatographed on a silica gel column (ethyl acetate / petroleum ether = 0-20%) to obtain 5-amino-3-bromo-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 61-2 (9.5 g), with a yield of 38.2%.
[0738] MS:m / z(ESI):371.0[M-Boc+H] +
[0739] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.40(d,J=7.6Hz,1H),8.14(d,J=7.6Hz,1H),6.96(s,1H),1.58(s,9H).
[0740] Step 3: Preparation of N-(3-bromo-1H-pyrazol-5-yl)-2-chloro-6-(trifluoromethyl)nicotinamide
[0741]
[0742] 5-amino-3-bromo-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 61-2 (8.0 g, 17.1 mmol) was dissolved in anhydrous dichloromethane (20 mL), and a hydrochloric acid dioxane solution (4 M, 40 mL) was added, and the mixture was reacted at room temperature for 4 hours. The reaction solution was directly spin-dried to obtain N-(3-bromo-1H-pyrazol-5-yl)-2-chloro-6-(trifluoromethyl) nicotinamide Example 61-3 (6.2 g), with a yield of 98.4%.
[0743] MS:m / z(ESI):368.9[M+H] +
[0744] 1H NMR (400MHz, DMSO-d6) δ11.50(s,1H),8.39(d,J=7.6Hz,1H),8.10(d,J=7.6Hz,1H),6.53(s,1H).
[0745] Step 4: Preparation of 2-bromo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one
[0746]
[0747] N-(3-bromo-1H-pyrazol-5-yl)-2-chloro-6-(trifluoromethyl)nicotinamide Example 61-3 (6.2 g, 16.8 mmol) was dissolved in N,N-dimethylformamide (80 mL), potassium carbonate (6.96 g, 50.4 mmol) was added, and the mixture was heated to 120° C. for 2 hours. The reaction solution was cooled to room temperature and used directly in the next step.
[0748] MS:m / z(ESI):333.0[M+H] +
[0749] Step 5: Preparation of 2-(2-bromo-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0750]
[0751] Potassium carbonate (6.96 g, 50.4 mmol) and 2-bromo-N-(5-fluoropyridin-2-yl)acetamide (4.7 g, 20.2 mmol) were added to the reaction solution of 2-bromo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one Example 61-4 (NA, 16.8 mmol) in N,N-dimethylformamide (80 mL), and reacted at 40°C for 2 hours. The reaction solution was cooled to room temperature, poured into 300 mL of water, and extracted with ethyl acetate (200 mL*3). The organic phases were combined, washed successively with water (200 mL*2) and saturated sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from ethyl acetate to obtain the title product 2-(2-bromo-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridine[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide Example 61-A.
[0752] 1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),8.84(d,J=8.0Hz,1H),8.37(s,1H),8.09( d,J=8.0Hz,1H),8.07–8.02(m,1H),7.80–7.73(m,1H),6.78(s,1H),4.96(s,2H).
[0753] MS m / z(ESI):486.2[M+H] + .
[0754] Step 6: Preparation of tert-butyl 3-(4-(2-(((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-5-oxo-8-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-2-yl)azetidine-1-carboxylate
[0755]
[0756] Zinc powder (<10 μM, 20.3g) is stirred with 1M HCl (100mL).After 2 hours, the suspension is filtered, and the solid is washed with water (x 2), then with ethanol (x 2), and finally with ether (x 2).The solid is dried under vacuum and stored under nitrogen.Zinc powder (0.60g, 9.16mmol washed) is stirred vigorously in dimethylacetamide (4mL) under nitrogen, and the resulting suspension is heated to 65 ° C.Trimethylchlorosilane (0.12g, 0.14mL, 1.14mmol) and 1,2-dibromoethane (0.098mL, 1.14mmol) are added, and stirring is continued for 40 minutes.Then in 0.5 hour, a solution of 3-iodoazetidine-1-carboxylic acid tert-butyl esters (2.0g, 7.06mmol) in dimethylacetamide (4mL) is added dropwise to the reaction mixture. The resulting suspension was stirred at 65°C for 0.5 h and then cooled to room temperature. The reaction mixture was used in the next step without treatment. A solution of Example 2 (200 mg, 0.41 mmol) and Pd(dppf)Cl2 (33 mg, 0.04 mmol) in DMA (3 mL) was added to the above prepared solution and heated to 85°C for 16 h. The mixture was prepared to give Example 61-B (100 mg, 43%).
[0757] MS m / z(ESI):562.17[M+H] + .
[0758] Step 7: Preparation of 2-(2-(azacyclobutane-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0759]
[0760] 4M / L HCl / methanol (6mL) was added to a solution of Example 61-B (100 mg, 0.18 mmol) in DCM (2mL), and the reaction solution was stirred at room temperature for 2 hours. The reaction solution was directly spin-dried to obtain Example 61-C (80 mg, 97%).
[0761] MS m / z(ESI):462.17[M+H] + .
[0762] Step 8: Preparation of 2-(2-(1-(2,2-difluoroethyl)azetidin-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0763]
[0764] Potassium carbonate (46 mg, 0.33 mmol) and difluoroiodoethane (42 mg, 0.22 mmol) were added to a solution of Example 61-C (50 mg, 0.11 mmol) in DMF (5 mL) at room temperature. The mixture was heated to 40°C and stirred for 2 h. After cooling, water was added, and the precipitate was filtered and washed with ethyl acetate, and purified to give Example 61 (26 mg, yield: 46%).
[0765] MS m / z(ESI):526.4[M+H] + .
[0766] Embodiment 62
[0767] 2-(2-cyclohexyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0768] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0769]
[0770] The synthesis method of Example 62 was followed by referring to the synthesis method of Example 4 to obtain the title compound Example 62 (15 mg, 31%).
[0771] MS m / z(ESI):489.5[M+H] + .
[0772] 1 H NMR (400MHz, DMSO-d6) δ11.01(s,1H),8.74(d,J=8.0Hz,1H),8.33(s,1H),8.04–7.93(m,2H),7.72(t,J=9.1Hz,1H),6.36 (s,1H),4.91(s,2H),2.69(s,1H),1.90(d,J=12.5Hz,3H),1.70(dd,J=34.4,12.4Hz,3H),1.40(td,J=24.5,12.0Hz,4H).
[0773] Embodiment 63
[0774] N-(5-fluoropyridin-2-yl)-2-(2-(3-methylpyridin-4-yl)-5-oxo-8-(trifluoromethyl)pyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0775]
[0776] The synthesis method of Example 63 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 63 (15 mg, 30%).
[0777] MS m / z(ESI):498.4[M+H] + .
[0778] 1 H NMR(400MHz,DMSO-d6)δ11.12(s,1H),8.95–8.74(m,3H),8.38(s,1H),8.27 –8.00(m,3H),7.76(t,J=9.0Hz,1H),7.25(s,1H),5.09(s,2H),2.72(s,3H).
[0779] Embodiment 64
[0780] N-(5-fluoropyridin-2-yl)-2-(2-(2-methylpyridin-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolin[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0781]
[0782] The synthesis method of Example 64 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 64 (15 mg, 30%).
[0783] MS m / z(ESI):498.4[M+H] + .
[0784] 1 H NMR(400MHz,DMSO-d6)δ11.13(s,1H),8.90–8.62(m,3H),8.36(s,1H),8.1 5–7.99(m,2H),7.93–7.68(m,2H),7.11(s,1H),5.08(s,2H),2.96(s,3H).
[0785] Embodiment 65
[0786] 2-(2,4-dimethylpyridin-3-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0787]
[0788] The synthesis method of Example 65 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 65 (10 mg, 33%).
[0789] MS m / z(ESI):512.4[M+H] + .
[0790] Embodiment 66
[0791] N-(5-fluoropyridin-2-yl)-2-(5-oxo-2,8-bis(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0792]
[0793] The synthesis method of Example 66 was carried out by referring to the synthesis method of Example 1 to obtain the title compound Example 66 (10 mg, 33%).
[0794] MS m / z(ESI):475.3[M+H] + .
[0795] 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.91(d,J=8.0Hz,1H),8.37(d,J=3.1Hz,1H),8.1 9(d,J=8.1Hz,1H),8.14–7.98(m,1H),7.76(t,J=8.8Hz,1H),7.13(s,1H),5.04(s,2H).
[0796] Embodiment 68
[0797] 2-(2-cyano-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0798] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0799]
[0800] Step 1: Preparation of 2-(2-cyano-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0801]
[0802] Example 61-A (300 mg, 0.619 mmol) and Zn(CN)2 (300 mg, 2.56 mmol), Pd2(dba)3 (20 mg, 0.022 mmol), Pd(dppf)Cl2 (30 mg, 0.036 mmol) and Zn powder (10 mg, 0.154 mmol) were dissolved in DMA (10 mL) at room temperature and nitrogen was bubbled in for 2 minutes. Then microwave heating at 140 degrees was performed for 8 hours. Cooled to room temperature, extracted with ethyl acetate (50 mL), and the organic phase was washed twice with saturated brine. The organic phase was dried (Na2SO4), concentrated under reduced pressure, and sent to p-HPLC (FA) to obtain 100 mg (38% yield) of the title compound.
[0803] 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.92(d,J=8.2Hz,1H),8.37(d,J=3.1Hz,1H), 8.22(d,J=7.9Hz,1H),8.05(s,1H),7.77(t,J=8.6Hz,1H),7.24(s,1H),5.01(s,2H).
[0804] MS m / z(ESI):432.3[M+H] + .
[0805] Embodiment 69
[0806] N-(5-fluoropyridin-2-yl)-2-(2-(2-hydroxypropan-2-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0807]
[0808] Step 1: Preparation of N-(5-fluoropyridin-2-yl)-2-(2-(2-hydroxypropane-2-yl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0809]
[0810] At 25°C, Example 69-1 (100 mg, 0.22 mmol) (the synthesis method of Example 69-1 refers to the operation of Example 6) was dissolved in dimethoxyethane (2 ml) / MeOH (2 ml), and cobalt (II) isotetraphenylporphyrin (1.3 mg, 0.002 mmol) and tetraethylammonium borohydride (80.2 mg, 0.55 mmol) were added in sequence. The reaction mixture was stirred for 1.25 hours. The reaction was terminated, quenched by adding saturated aqueous ammonium chloride solution (50 mL), and the mixture was extracted with ethyl acetate (3×40 mL). The combined organic phases were washed with saturated aqueous sodium chloride solution (1×80 mL), dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The crude product was purified to obtain the title compound (42 mg, 42% yield).
[0811] MS m / z(ESI):465.1[M+H] + .
[0812] 1 H NMR (400MHz, DMSO) δ11.07(s,1H),8.81(d,J=7.9Hz,1H),8.37(s,1H),8.12–7.92(m,2H),7.76(s,1H),6.44(s,1H),4.99(s,2H),1.51(s,6H).
[0813] Embodiment 70
[0814] N-(5-fluoropyridin-2-yl)-2-(2-isobutyl-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridine
[0815] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0816]
[0817] The synthesis of Example 70 was carried out by referring to the method of Example 1, except that 3-(isobutyl)-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (26 mg, 26% yield).
[0818] MS m / z(ESI):463.4[M+H] + .
[0819] 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.79(d,J=8.0Hz,1H),8.37(s,1H),8.07-8.03(m,1H),8.00(d,J=8.0Hz,1 H),7.78-7.73(m,1H),6.33(s,1H),4.96(s,2H),2.55(d,J=8.2Hz,2H),2.04-1.93(m,1H),0.95(d,J=6.4Hz,6H).
[0820] Embodiment 71
[0821] N-(5-fluoropyridin-2-yl)-2-(2-morpholin-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridine
[0822] [3,2-e]pyrimidin-4(5H)-yl)acetamide
[0823]
[0824] The synthesis of Example 71 was carried out by referring to the method of Example 1, except that 3-(morpholinyl)-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (14 mg, 35% yield).
[0825] MS m / z(ESI):492.4[M+H] + .
[0826] Embodiment 74
[0827] 2-(2-(azetidine-1-carbonyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridinyl
[0828] [3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0829]
[0830] Step 1: Preparation of 2-(2-(azetidine-1-carbonyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridinyl[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0831]
[0832] To a DMF (2mL) solution of Example 74-1 (100 mg, 0.22 mmol) (the synthesis method of Example 74-1 refers to Example 8-3) and HATU (83.4 mg, 0.22 mmol) was added DIPEA (0.1 mL, 0.6 mmol). The mixture was stirred at room temperature for 30 minutes, and then azetidine (12.5 mg, 0.22 mmol) was added to the mixture. The reaction was stirred at room temperature for 18 hours. Water (40 mL) was added to the reaction. The mixture was extracted with ethyl acetate (2×20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give Example 74 (56 mg, 52% yield).
[0833] MS m / z(ESI):490.1[M+H] + .
[0834] 1 H NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.86(d,J=8.1Hz,1H),8.37(s,1H),8.15–8.08(m,1H),8.04(s,1H),7.7 5(t,J=9.4Hz,1H),6.81(s,1H),5.04(s,2H),4.68–4.52(m,2H),4.08(t,J=7.5Hz,2H),2.34(d,J=9.1Hz,2H).
[0835] Embodiment 78
[0836] N-(5-fluoropyridin-2-yl)-2-(5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0837]
[0838] Step 1: Preparation of N-(1H-pyrazol-5-yl)-2-chloronicotinamide
[0839]
[0840] 1H-pyrazole-5-amine (1.66 g, 19.93 mmol), DIPEA (6.2 g, 49.8 mmol) and HATU (5.4 g, 0.144 mmol) were added to a DMF (30 mL) solution of 2-chloronicotinic acid (1.57 g, 9.96 mmol) in sequence under ice bath conditions, and stirred for 1 h after removing the ice bath. The mixture was prepared to give Example 78-1 (2.0 g, 90%).
[0841] MS m / z(ESI):291.0[M+H] + .
[0842] Step 2: Preparation of pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-5(4H)-one
[0843]
[0844] Potassium carbonate (1.61 g, 11.66 mmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (150.9 mg, 1.35 mmol) were added to a solution of Example 78-1 (2.0 g, 8.97 mmol) in DMF (50 mL), and the reaction solution was stirred at room temperature for 16 hours. The mixture was prepared to give Example 78-2 (1.6 g, 97%).
[0845] MS m / z(ESI):255.0[M+H] + .
[0846] Step 3: Preparation of 2-(2-(tert-butyl)-5-oxopyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0847]
[0848] Potassium carbonate (2.23 g, 16.11 mmol) and Example 1-3 (2.25 g, 9.67 mmol) were added to a solution of Example 78-2 (1.5 g, 8.06 mmol) in DMF (30 mL) at room temperature. The mixture was heated to 80°C and stirred for 2 h. After cooling, water was added, the precipitate was filtered and washed with ethyl acetate, and purified to obtain Example 78 (2.1 g, yield: 78%).
[0849] 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.83(d,J=8.0Hz,1H),8.37(d,J=3.2Hz,1H),8.06(d,J=8. 0Hz,1H),8.05–8.02(m,1H),7.98(d,J=2.0Hz,1H),7.78–7.73(m,1H),6.46(s,1H),5.00(s,2H).
[0850] MS m / z(ESI):407.3[M+H] + .
[0851] Embodiment 79
[0852] 2-(2-Chloro-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0853] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0854]
[0855] The synthesis of Example 79 was carried out by referring to the method of Example 1, except that 3-chloro-1H-pyrazole-5-amine was substituted for 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound (31 mg, 26% yield).
[0856] 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.84(d,J=8.1Hz,1H),8.36(s,1H),8.15–7.99(m,2H),7.76(t,J=9.0Hz,1H),6.73(s,1H),4.96(s,2H).
[0857] MS m / z(ESI):441.7[M+H] + .
[0858] Embodiment 80
[0859] 2-(3-cyano-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidine-4(5H)-
[0860] yl)-N-(5-fluoropyridin-2-yl)acetamide
[0861]
[0862] The synthesis of Example 80 was carried out by referring to the method of Example 1, except that 4-cyano-1H-pyrazole-5-amine was used instead of 3-(tert-butyl)-1H-pyrazole-5-amine to obtain the target compound.
[0863] Step 1: Preparation of tert-butyl 5-amino-4-cyano-1H-pyrazole-1-carboxylate
[0864]
[0865] 5-amino-1H-pyrazole-4-carbonitrile (2.0 g, 18.5 mmol) was dissolved in anhydrous dichloromethane (40 mL), triethylamine (3.74 g, 37.0 mmol) and di-tert-butyl dicarbonate (4.44 g, 20.4 mmol) were added, and the reaction was carried out at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and slurried with petroleum ether (50 mL) to obtain the title product 5-amino-4-cyano-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 80-1 (3.5 g), with a yield of 90.9%.
[0866] 1 H NMR (400MHz, DMSO-d6) δ7.77(s,1H),7.63(s,2H),1.56(s,9H).
[0867] Step 2: Preparation of tert-butyl 5-(2-chloro-6-(trifluoromethyl)nicotinamide)-4-cyano-1H-pyrazole-1-carboxylate
[0868]
[0869] 5-amino-4-cyano-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 80-1 (3.5 g, 16.8 mmol) was dissolved in anhydrous dichloromethane (50 mL), triethylamine (5.35 g, 7.37 mmol) was added, and a dichloromethane solution (50 mL) of 2-chloro-6-trifluoromethylnicotinic acid chloride (4.3 g, 17.6 mmol) prepared was added dropwise at 0°C under nitrogen protection, and the mixture was reacted at room temperature for 1 hour. The reaction solution was washed with water (50 mL*2) and saturated sodium chloride solution (50 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (ethyl acetate / petroleum ether = 0-40%) to obtain 5-(2-chloro-6-(trifluoromethyl)nicotinamide)-4-cyano-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 80-2 (2.8 g), with a yield of 38.2%.
[0870] MS:m / z(ESI):432.8[M+NH4] +
[0871] 1H NMR (400MHz, DMSO-d6) δ11.87(s,1H),9.23(s,1H),8.43(d,J=7.6Hz,1H),8.13(d,J=7.6Hz,1H),1.59(s,9H).
[0872] Step 3: Preparation of 2-chloro-N-(4-cyano-1H-pyrazol-5-yl)-6-(trifluoromethyl)nicotinamide
[0873]
[0874] 5-(2-chloro-6-(trifluoromethyl)nicotinamide)-4-cyano-1H-pyrazole-1-carboxylic acid tert-butyl ester Example 80-2 (2.8 g, 6.73 mmol) was dissolved in anhydrous dichloromethane (10 mL), and a hydrochloric acid dioxane solution (4M, 30 mL) was added, and the mixture was reacted at room temperature for 5 hours. The reaction solution was directly spin-dried to obtain 2-chloro-N-(4-cyano-1H-pyrazol-5-yl)-6-(trifluoromethyl)nicotinamide Example 80-3 (2.1 g), with a yield of 98.8%.
[0875] MS:m / z(ESI):315.8[M+H] +
[0876] Step 4: Preparation of 5-oxo-8-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrido[3,2-e]pyrimidine-3-carbonitrile
[0877]
[0878] 2-Chloro-N-(4-cyano-1H-pyrazol-5-yl)-6-(trifluoromethyl)nicotinamide Example 80-3 (2.1 g, 6.65 mmol) was dissolved in N,N-dimethylformamide (40 mL), potassium carbonate (1.84 g, 13.3 mmol) was added, and the mixture was heated to 120°C for 2 hours. The reaction solution was cooled to room temperature, the pH was adjusted to 6 with 1M dilute hydrochloric acid, and extracted with ethyl acetate (100 mL*2). The organic phases were combined, washed with water (100 mL*2) and saturated sodium chloride solution (100 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and slurried with ethyl acetate (15 mL) to obtain 5-oxo-8-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyridine[3,2-e]pyrimidine-3-carbonitrile Example 80-4 (1.3 g), with a yield of 69.9%.
[0879] MS:m / z(ESI):279.8[M+H] +
[0880] Step 4: Preparation of 2-(3-cyano-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide
[0881]
[0882] 5-Oxo-8-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyridine[3,2-e]pyrimidine-3-carbonitrile Example 80-4 (500 mg, 1.79 mmol) was dissolved in N,N-dimethylformamide (20 mL), potassium carbonate (371 mg, 2.69 mmol) and 2-bromo-N-(5-fluoropyridin-2-yl)acetamide (501 mg, 2.15 mmol) were added, and the mixture was reacted at 40° C. for 2 hours. The reaction solution was cooled to room temperature, poured into 100 mL of water, and extracted with ethyl acetate (50 mL*2). The organic phases were combined, washed with water (50 mL*2) and saturated sodium chloride solution (50 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was slurried in ethyl acetate. The obtained mother liquor was concentrated under reduced pressure and then prepared by reverse HPLC to obtain the title product 2-(3-cyano-5-oxo-8-(trifluoromethyl)pyrazol[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)-N-(5-fluoropyridin-2-yl)acetamide Example 80. MS m / z(ESI):432.3[M+H] + .
[0883] 1 H NMR (400MHz, DMSO-d6) δ11.2(s,1H),8.93(d,J=8.0Hz,1H),8.58(s,1H),8.38(d,J=3 .2Hz,1H),8.20(d,J=8.0Hz,1H),8.07-8.04(m,1H),7.81-7.75(m,1H),5.19(s,2H).
[0884] Embodiment 81
[0885] 4-(2-((5-fluoropyridin-2-yl)amino)-2-oxoethyl)-N-methyl-5-oxo-8-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyridinyl[3,2-e]pyrimidine-2-carboxamide
[0886]
[0887] The synthesis of Example 81 was carried out by referring to the method of Example 74, except that methylamine was used instead of azetidine to obtain the target compound (48 mg, 61% yield).
[0888] MS m / z(ESI):464.1[M+H] + .
[0889] 1 H NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.88(d,J=8.0Hz,1H),8.53(d,J=5.4Hz,1H),8.37(s,1H),8.13 (d,J=8.1Hz,1H),8.04(s,1H),7.76(t,J=8.9Hz,1H),6.84(s,1H),5.05(s,2H),2.80(d,J=4.6Hz,3H).
[0890] Embodiment 82
[0891] N-(5-fluoropyridin-2-yl)-2-(2-(hydroxymethyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-
[0892] a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0893]
[0894] Step 1: Preparation of N-(5-fluoropyridin-2-yl)-2-(2-(hydroxymethyl)-5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin[3,2-e]pyrimidin-4(5H)-yl)acetamide
[0895]
[0896] At 0°C, diisobutylaluminum hydride (1M toluene solution, 0.66mL, 0.66mmol) was added to a solution of Example 82-1 (100mg, 0.22mmol) (the synthesis method of Example 82-1 refers to Example 8-2) in THF (2mL), and the mixture was stirred at room temperature overnight. Rochelle's salt solution (1.0M, 5ml) was added; then ethyl acetate (5mL) was added, and the resulting suspension was stirred at room temperature until transparent phase separation was achieved, the organic phase was separated, and the aqueous phase was extracted with EtOAc (3×40ml). The combined organic layer was washed with saturated sodium bicarbonate aqueous solution (50mL) and saturated brine (50mL), dried over anhydrous sodium sulfate, and concentrated and purified to obtain the target compound (32mg, 34% yield).
[0897] MS m / z(ESI):437.1[M+H] + .
[0898] 1H NMR (400MHz, DMSO) δ11.06 (s, 1H), 8.82 (d, J = 7.9Hz, 1H), 8.37 (s, 1H), 8.0 2(m,2H),7.76(s,1H),6.40(s,1H),5.44(s,1H),5.00(s,2H),4.56(s,2H).
[0899] Embodiment 83
[0900] N-(5-chloropyridin-2-yl)-2-(5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridinyl[3,2-e]
[0901] Pyrimidin-4(5H)-yl)acetamide
[0902]
[0903] The synthesis of Example 83 was carried out by referring to the method of Example 78, except that 5-chloropyridin-2-amine was used instead of 5-fluoropyridin-2-amine to obtain the target compound (23 mg, 54% yield).
[0904] MS m / z(ESI):423.1[M+H] + .
[0905] 1 H NMR (400MHz, DMSO-d6) δ11.14(s,1H),8.84(d,J=8.0Hz,1H),8.42(d,J=2.6Hz,1 H),8.05(t,J=9.3Hz,2H),7.99–7.89(m,2H),6.47(d,J=2.0Hz,1H),5.02(s,2H).
[0906] Embodiment 84
[0907] N-(5-chloropyrimidin-2-yl)-2-(5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridinyl[3,2-e]
[0908] Pyrimidin-4(5H)-yl)acetamide
[0909]
[0910] The synthesis of Example 84 was carried out by referring to the method of Example 78, except that 5-chloropyrimidine-2-amine was substituted for 5-fluoropyridin-2-amine to obtain the target compound (21 mg, 53% yield).
[0911] MS m / z(ESI):424.1[M+H] + .
[0912] 1 H NMR (400MHz, DMSO-d6) δ11.29(s,1H),8.95–8.72(m,3H),8.06(d,J=8.0Hz,1H),7.98(d,J=2.0Hz,1H),6.46(d,J=2.0Hz,1H),5.16(s,2H).
[0913] Embodiment 85
[0914] N-(3,5-difluoropyridin-2-yl)-2-(5-oxo-8-(trifluoromethyl)pyrazolo[1,5-a]pyridin-
[0915] [3,2-e]pyrimidin-4(5H)-ylacetamide
[0916]
[0917] The synthesis of Example 85 was carried out by referring to the method of Example 78, except that 3,5-difluoropyridine was used instead of 5-fluoropyridin-2-amine to obtain the target compound (25 mg, 46% yield).
[0918] MS m / z(ESI):425.1[M+H] + .
[0919] 1 H NMR (400MHz, DMSO-d6) δ11.32(s,1H),8.82(d,J=8.0Hz,1H),8.56(dd,J=10.2,2.2Hz,1H),8.12–7.91(m,3H),6.45(d,J=2.0Hz,1H),5.01(s,2H).
[0920] Biological test evaluation
[0921] The present invention is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present invention.
[0922] Test Example 1: Determination of the Effect of the Compounds of the Invention on Calcium Ion Fluidity in Cells Stably Expressing 1321N1-hP2X3 Receptors
[0923] Purpose:
[0924] The inhibitory activity of the compounds on 1321N1-hP2X3 receptor was determined.
[0925] Experimental instruments:
[0926] 384-well cell plate (Corning; 3712);
[0927] 384-well compound plate (Corning; 3657);
[0928] 384-well assay plate (LABCYTE; P-05525);
[0929] FLIPR (Molecular Devices).
[0930] Experimental reagents:
[0931] DMEM (Gibco; 11965);
[0932] FBS (Gibco; 10099-141);
[0933] Hygromycin B (Invitrogen, 10687010);
[0934] Matrix (Thermo; 5416);
[0935] DMSO (Sigma; D2650);
[0936] HBSS (Invitrogen; 14025);
[0937] HEPES (Invitrogen; 15630080);
[0938] Probenecid (Sigma; P8761);
[0939] Versene (Gibco; 15040066);
[0940] G418 (Sigma; G5013);
[0941] Calcium 4Assay Kit (Molecular Devices; R8141);
[0942] α,β-meATP (Sigma; M6517);
[0943] ATP hydrolytic enzyme (Sigma; A7646);
[0944] Stable cell line: 1321N1-hP2X3 (provided by Shanghai Ruizhi Chemical Research Co., Ltd.).
[0945] Experimental methods:
[0946] 1. Reagent preparation:
[0947] Assay buffer: 1*HBSS+20mM HEPES;
[0948] Cell culture medium: DMEM + 10% FBS + 75 μg / mL hygromycin B + 300 μg / mL G418;
[0949] Plating medium: DMEM + 10% DPBS;
[0950] 0.5*Dye: 10*Dye stock+1.25Probenecid+1*assay buffer+0.5U / mL ATPhydrolytic enzyme;
[0951] 2. The cell lines were cultured in cell culture medium at 37°C, 5% CO2 until the confluence reached 70% to 90%. The culture medium was discarded, the cells were removed, 2 mL of Versene was added, and the cells were placed in a 37°C incubator for 2-5 min. 10 mL of plating medium was added to collect the cells. The cells were counted and 50 μL (1×10 4 The cells were seeded into 384-well plates at a density of 10 cells / well and incubated for 16-24 hours (at least overnight).
[0952] 3. Discard the culture medium, add 30 μL 1X dye, and incubate at 37°C in the dark for 60 min.
[0953] 4. Dissolve the compound powder in DMSO to a 20 mM stock solution, prepare the 180X compound required for testing, and serially dilute to 10 concentration points.
[0954] 5. Prepare the compound plate: Use ECHO to transfer 500 nL of 180X compound to the compound plate (source plate for FLIPR), add 30 μL of assay buffer to each well, and shake gently for 20-40 minutes.
[0955] 6. On-machine detection: Take 15 μL of 3X compound to each well and add it to the cell plate. Load the FLIPR instrument and detect calcium signals. After 15 minutes, add 22.5 μL of 3X agonist (EC 80 concentration) and detect calcium signals.
[0956] Experimental data processing method:
[0957] The calcium signal is read by FLIPR. The calculated output for each sampling time point in the experiment is the ratio of the 340 / 510nm to 380 / 510nm wavelength signals. The maximum minus the minimum is calculated from the ratio signal curve.
[0958] The IC of the compound was calculated by fitting the percent inhibition and ten-point concentration data to a parametric nonlinear logistic formula using GraphPad prism. 50 value.
[0959] Experimental results:
[0960] The results of the example compounds of the present invention in the 1321N1-hP2X3 receptor cell functional calcium flux test are shown in Table 1:
[0961] Table 1
[0962]
[0963]
[0964] Experimental conclusion:
[0965] The above data show that the compounds of the present invention exhibit good inhibitory effects in the 1321N1-hP2X3 receptor cell functional calcium flux test.
[0966] Test Example 2: Determination of the Effect of the Compounds of the Invention on Calcium Ion Fluidity in Cells Stably Expressing 1321N1-hP2X2 / 3 Receptors
[0967] Purpose:
[0968] The inhibitory activity of the compounds on 1321N1-hP2X2 / 3 receptor was determined.
[0969] Experimental instruments:
[0970] 384-well cell plate (Corning; 3712);
[0971] 384-well compound plate (Corning; 3657);
[0972] 384-well assay plate (LABCYTE; P-05525);
[0973] FLIPR (Molecular Devices).
[0974] Experimental reagents:
[0975] DMEM (Gibco; 11965);
[0976] FBS (Gibco; 10099-141);
[0977] Hygromycin B (Invitrogen, 10687010);
[0978] Matrix (Thermo; 5416);
[0979] DMSO (Sigma; D2650);
[0980] HBSS (Invitrogen; 14025);
[0981] HEPES (Invitrogen; 15630080);
[0982] Probenecid (Sigma; P8761);
[0983] Versene (Gibco; 15040066);
[0984] G418 (Sigma; G5013);
[0985] Calcium 4Assay Kit (Molecular Devices; R8141);
[0986] α,β-meATP (Sigma; M6517);
[0987] ATP hydrolytic enzyme (Sigma; A7646);
[0988] Stable cell line: 1321N1-hP2X2 / 3 (provided by Shanghai Ruizhi Chemical Research Co., Ltd.).
[0989] Experimental methods:
[0990] 1. Reagent preparation:
[0991] Assay buffer: 1*HBSS+20mM HEPES;
[0992] Cell culture medium: DMEM + 10% FBS + 75 μg / mL hygromycin B + 150 μg / mL G418;
[0993] Plating medium: DMEM + 10% DPBS;
[0994] 0.5*Dye: 10*Dye stock+1.25Probenecid+1*assay buffer+0.5U / mL ATPhydrolytic enzyme;
[0995] 2. The cell lines were cultured in cell culture medium at 37°C, 5% CO2 until the confluence reached 70% to 90%. The culture medium was discarded, the cells were removed, 2 mL of Versene was added, and the cells were placed in a 37°C incubator for 2-5 min. 10 mL of plating medium was added to collect the cells. The cells were counted and 50 μL (1×10 4 The cells were seeded into 384-well plates at a density of 10 cells / well and incubated for 16-24 hours (at least overnight).
[0996] 3. Discard the culture medium, add 30 μL 1X dye, and incubate at 37°C in the dark for 60 min.
[0997] 4. Dissolve the compound powder in DMSO to a 20 mM stock solution, prepare the 180X compound required for testing, and serially dilute to 10 concentration points.
[0998] 5. Prepare the compound plate: Use ECHO to transfer 500 nL of 180X compound to the compound plate (source plate for FLIPR), add 30 μL of assay buffer to each well, and shake gently for 20-40 minutes.
[0999] 6. On-machine detection: Take 15 μL of 3X compound to each well and add it to the cell plate. Load the FLIPR instrument and detect calcium signals. After 15 minutes, add 22.5 μL of 3X agonist (EC 80 concentration) and detect calcium signals.
[1000] Experimental data processing method:
[1001] The calcium signal is read by FLIPR. The calculated output for each sampling time point in the experiment is the ratio of the 340 / 510nm to 380 / 510nm wavelength signals. The maximum minus the minimum is calculated from the ratio signal curve.
[1002] The IC of the compound was calculated by fitting the percent inhibition and ten-point concentration data to a parametric nonlinear logistic formula using GraphPad prism. 50 value.
[1003] Experimental results:
[1004] The results of the test of the compounds of the present invention on the functional calcium flow of 1321N1-hP2X2 / 3 receptor cells are shown in Table 2:
[1005] Table 2
[1006]
[1007] Experimental conclusion:
[1008] The above data show that the compounds of the present invention show a small inhibitory effect in the 1321N1-h2X2 / 3 receptor cell functional calcium flux test.
[1009] Test Example 3: Pharmacokinetics in Balb / C mice
[1010] 1. Research objectives:
[1011] Balb / C mice were used as test animals to study the pharmacokinetic behavior of the following compound examples in the plasma of mice after oral administration at a dose of 5 mg / kg.
[1012] 2. Experimental plan
[1013] 2.1 Trial Drugs:
[1014] The embodiments of the present invention are self-made.
[1015] 2.2 Experimental Animals:
[1016] Balb / C Mouse 6 / example, male, Shanghai JXJ Experimental Animal Co., Ltd., animal production license number (SCXK (Shanghai) 2013-0006N0.311620400001794).
[1017] 2.3 Drug preparation:
[1018] Weigh 5g of hydroxyethyl cellulose (HEC, CMC-Na, viscosity: 800-1200Cps), dissolve it in 1000mL of purified water, add 10g of Tween 80 and mix well to form a clear solution.
[1019] 2.4 Administration:
[1020] Balb / C mice, male, were fasted overnight and administered orally at a dose of 5 mg / kg in a volume of 10 mL / kg.
[1021] 2.5 Sample collection:
[1022] Before and after administration of the mice, 0.04 mL of blood was collected from the eye sockets at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours, placed in EDTA-K2 tubes, centrifuged at 6000 rpm at 4°C for 6 min to separate plasma, and stored at -80°C.
[1023] 2.6 Sample processing:
[1024] 1) Add 160uL acetonitrile to 20uL of plasma sample for precipitation, mix and centrifuge at 3500×g for 5 to 20 minutes.
[1025] 2) Take 100uL of the supernatant solution after treatment and perform LC / MS / MS analysis to determine the concentration of the test compound.
[1026] 2.7 Liquid phase analysis
[1027] Liquid phase conditions: Shimadzu LC-20AD pump
[1028] Mass spectrometry conditions: AB Sciex API 4000 mass spectrometer
[1029] Chromatographic column: phenomenex Gemiu 5um C18 50×4.6mm
[1030] Mobile phase: Liquid A is 0.1% formic acid aqueous solution, Liquid B is acetonitrile
[1031] Flow rate: 0.8mL / min
[1032] Elution time: 0-4.0 minutes, eluent is as follows:
[1033]
[1034] 3. Test results and analysis
[1035] The main pharmacokinetic parameters were calculated using WinNonlin 8.2. The results of the mouse pharmacokinetic experiment are shown in Table 3 below:
[1036] Table 3 Results of mouse pharmacokinetic experiments
[1037]
[1038] Note: 0.5% CMC-Na (1% Tween 80)
[1039] Experimental conclusion:
[1040] From the results of the mouse pharmacokinetic experiment in the table, it can be seen that the compounds of the present invention show good metabolic properties, exposure AUC and maximum blood drug concentration C max All performed well.
[1041] Test Example 4: Pharmacokinetics in rats
[1042] 1. Research objectives:
[1043] SD rats were used as test animals to study the pharmacokinetic behavior of the following compound examples in rat plasma after oral administration at a dose of 5 mg / kg.
[1044] 2. Experimental plan
[1045] 2.1 Trial Drugs:
[1046] The embodiments of the present invention are self-made.
[1047] 2.2 Experimental Animals:
[1048] There were 3 male SD rats in each group. Shanghai JXJ Experimental Animal Co., Ltd., animal production license number (SCXK (Shanghai) 2013-0006N0.311620400001794).
[1049] 2.3 Drug preparation:
[1050] Weigh 5g of hydroxyethyl cellulose (HEC, CMC-Na, viscosity: 800-1200Cps), dissolve it in 1000mL of purified water, add 10g of Tween 80 and mix well to form a clear solution.
[1051] 2.4 Administration:
[1052] Three male SD rats were fasted overnight and then PO-administered at a dose of 5 mg / kg in a dosing volume of 10 mL / kg.
[1053] 2.5 Sample collection:
[1054] Before and after administration, 0.2 mL of blood was collected from the jugular vein of rats at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours, placed in an EDTA-K2 tube, centrifuged at 6000 rpm for 6 min at 4°C to separate plasma, and stored at -80°C.
[1055] 2.6 Sample processing:
[1056] 1) 40uL of plasma sample was added to 160uL of acetonitrile for precipitation, and after mixing, centrifuged at 3500×g for 5 to 20 minutes.
[1057] 2) Take 100uL of the supernatant solution after treatment and perform LC / MS / MS analysis to determine the concentration of the test compound.
[1058] 2.7 Liquid phase analysis
[1059] Liquid phase conditions: Shimadzu LC-20AD pump
[1060] Mass spectrometry conditions: AB Sciex API 4000 mass spectrometer
[1061] Chromatographic column: phenomenex Gemiu 5um C18 50×4.6mm
[1062] Mobile phase: Liquid A is 0.1% formic acid aqueous solution, Liquid B is acetonitrile
[1063] Flow rate: 0.8mL / min
[1064] Elution time: 0-4.0 minutes, eluent is as follows:
[1065]
[1066]
[1067] 3. Test results and analysis
[1068] The main pharmacokinetic parameters were calculated using WinNonlin 8.2. The results of the rat pharmacokinetic experiment are shown in Table 4 below:
[1069] Table 4 Results of rat pharmacokinetic experiments
[1070]
[1071] Note: 0.5% CMC-Na (1% Tween 80)
[1072] 4. Experimental conclusion:
[1073] From the results of the rat pharmacokinetic experiment in the table, it can be seen that at a dose of 5 mg / kg, the compounds of the embodiments of the present invention exhibit good metabolic properties, exposure AUC and maximum blood drug concentration C max All performed well.
[1074] Test Example 5: Liver microsome metabolic stability test
[1075] 1. Experimental purpose:
[1076] The purpose of this experiment is to detect the stability of the example compounds in mouse, rat, dog and human liver microsomes.
[1077] 2. Experimental steps:
[1078] 2.1 Preparation of compound working solution
[1079] Preparation of compound working solution: Add compound stock solution into phosphate buffer to a final concentration of 20 μM.
[1080] 2.2 Preparation of liver microsome working solution
[1081] Dilute with 100 mM phosphate buffer to a final concentration of 0.625 mg / mL.
[1082] 2.3 Preparation of NADPH and UDPGA
[1083] NADPH (reduced nicotinamide adenine dinucleotide phosphate) and UDPGA (uridine diphosphate glucuronic acid) were weighed and added to 100 mM phosphate buffer to a final concentration of 20 mM.
[1084] 2.4 Prepare the punching agent
[1085] Weigh 1 mg of Alamethicin and add 200 μL of DMSO to prepare a 5 mg / mL solution, and then dilute with phosphate buffer to a final concentration of 50 μg / mL.
[1086] 2.5 Preparation of reaction termination solution
[1087] Stop solution: cold acetonitrile containing 100 ng / mL labetalol hydrochloride and 400 ng / mL tolbutamide as internal standard.
[1088] 2.6 Incubation process
[1089] 400 μL of prepared liver microsomes, 25 μL of compound working solution and 25 μL of Lamethicin were added to a 96-well plate and pre-incubated at 37°C for 10 min. Then 50 μL of prepared NADPH / UDPGA was added to start the reaction and incubated at 37°C. The total volume of the reaction system was 500 μL, and the final contents of each component were as follows:
[1090] Element content Liver microsomes 0.5mg / mL Compound 1μM NADPH 2mM UDPGA 2mM Alamethicin 2.5 μg / mL
[1091] 2.7 Sample analysis
[1092] 2.7.1 Chromatographic conditions:
[1093] Instrument: Shimadzu LC-30AD;
[1094] Chromatographic column: C18 (50*4.6mm, 5μm particle size);
[1095] Mobile phase: A: 0.1% formic acid solution, B: methanol
[1096] Washing gradient: 0.2-1.6 min 5% A to 95% A, 3.0-3.1 min 95% A to 5% A
[1097] Running time: 4.0min.
[1098] 2.7.2 Mass spectrometry conditions:
[1099] Instrument: API5500 liquid chromatography-mass spectrometer, AB Sciex;
[1100] Ion source: electrospray ionization source (ESI);
[1101] Drying gas: N2, temperature 500℃;
[1102] Electrospray voltage: 5000 V;
[1103] Detection method: positive ion detection;
[1104] Scanning mode: reaction monitoring (MRM) mode.
[1105] 3. Experimental results:
[1106] Table 5 Metabolic stability results of the compounds in the examples in liver microsomes
[1107]
[1108]
[1109] 4. Experimental conclusion:
[1110] The above data show that the compounds of the present invention have good metabolic stability in liver microsomes of mice, rats, dogs and humans.
[1111] Test Example 6: Plasma protein binding rate experiment
[1112] 1. Experimental purpose:
[1113] The purpose of this experimental method is to detect the plasma protein binding of the example compounds in plasma.
[1114] 2. Experimental instruments and materials:
[1115] Liquid phase mass spectrometer, centrifuge, vortexer, pipette, continuous liquid adder, 96-well plate, tissue homogenizer (for tissue sample analysis), 50% methanol aqueous solution, acetonitrile solution with internal standard, blank matrix (plasma, urine or tissue homogenate, etc.)
[1116] 3. Experimental steps:
[1117] 3.1 Preparation of stock solution of test substance A
[1118] The example compounds were prepared into 1 mM solution A using DMSO;
[1119] 3.2 Preparation of plasma solution B
[1120] Take solution A and add it to the plasma solution to prepare 5uM solution B;
[1121] 3.3 Processing Flow
[1122] 1) Add 200uL solution B into the membrane;
[1123] 2) Add 350uL PBS outside the membrane;
[1124] 3) Incubate in a 37°C water bath for 6 h;
[1125] 4) The samples are processed, diluted and subjected to mass spectrometry detection.
[1126] 4. Chromatographic conditions:
[1127] Instrument: Shimadzu LC-20AD;
[1128] Column: Phenomenex C18 (50*4.6mm, 5μm particle size);
[1129] Mobile phase: A: acetonitrile, B: 0.1% formic acid solution 0-0.5 min: 5% A→90% A, 2.0-2.1 min: 90% A→5% A; flow rate: 0.8 mL / min; running time: 5.0 min; injection volume: 5 μL.
[1130] 5. Mass spectrometry conditions:
[1131] Instrument: API4000 liquid chromatography-mass spectrometer, AB Company, USA;
[1132] The ion source was electrospray ionization (ESI);
[1133] Drying gas (N2) temperature 500°C;
[1134] The electrospray voltage was 5500 V;
[1135] The detection method is positive ion detection;
[1136] The scanning mode was selected reaction monitoring (MRM) and the scanning time was 0.1 s.
[1137] 6. Experimental results:
[1138] Table 6: Plasma protein binding rate results of the example compounds
[1139]
[1140] 7. Experimental conclusion:
[1141] The above data show that the compounds of the present invention have high plasma protein binding rates and little species difference. Test Example 7: CYP enzyme single-point inhibition test
[1142] 1. Purpose of the experiment
[1143] The human liver microsome incubation system was used to quickly predict the inhibition of compounds on CYP450 enzyme subtypes using the single-point method.
[1144] 2. Experimental Procedure
[1145] 2.1 Solution preparation
[1146] 2.5mM NADPH, weigh 4.165mg NADPH (reduced nicotinamide adenine dinucleotide phosphate) and add 100mM phosphate buffer to 2mL. 0.25mg / mL microsomes, 50μL 20mg / mL microsomes, add 4mL 100mM phosphate buffer and mix well.
[1147] Preparation of test compound reaction solution
[1148] The compound of the example to be tested was weighed, diluted to 10 mM with DMSO, and then diluted to 100 μM with 100 mM phosphate buffer.
[1149] 2.2 Experimental process:
[1150] 1. In a 96-well plate, add 40 μL liver microsomes, 10 μL substrate, and 10 μL test compound and pre-incubate for 3 min.
[1151] 2. Add 40 μL of NADPH.
[1152] 3. At 20 min, add 300 μL of acetonitrile stop solution containing internal standard.
[1153] 4. Centrifuge and inject.
[1154] 3. Experimental results:
[1155] Table 7 Single-site inhibition results of CYP enzymes by example compounds
[1156]
[1157]
[1158] Note: Strong inhibition: IC 50 <1μM; Moderate inhibition: 1μM <IC 50 <10μM; weak inhibition: IC 50 >10μM
[1159] 4. Experimental conclusion:
[1160] The above data show that the compounds of the embodiments of the present invention do not strongly inhibit various CYP enzyme subtypes and have a low DDI risk.
[1161] Test Example 8: hERG potassium channel inhibition activity test
[1162] 1. Cell Preparation
[1163] 7.1.1 CHO-hERG cells cultured at 175 cm 2When the cell density in the culture flask grows to 60-80%, remove the culture medium, wash once with 7 mL PBS, and then add 3 mL Detachin for digestion.
[1164] 7.1.2 After digestion is complete, add 7 mL of culture medium to neutralize, then centrifuge, aspirate the supernatant, and add 5 mL of culture medium to resuspend to ensure that the cell density is 2-5×10 6 / mL.
[1165] 2. Solution Preparation
[1166] Table 8 Composition of intracellular and extracellular fluids
[1167]
[1168] 3. Electrophysiological Recording Process
[1169] The single-cell high-impedance sealing and whole-cell pattern formation process are all automatically completed by the Qpatch instrument. After obtaining the whole-cell recording mode, the cell is clamped at -80 mV. Before a 5-second +40 mV depolarizing stimulus is given, a 50-millisecond -50 mV pre-voltage is given, and then repolarization to -50 mV is maintained for 5 seconds, and then returned to -80 mV. This voltage stimulus is applied every 15 seconds. After recording for 2 minutes, extracellular solution is given for 5 minutes of recording, and then the drug administration process begins. The compound concentration starts from the lowest test concentration, and each test concentration is given for 2.5 minutes. At least 3 cells (n≥3) are tested for each concentration.
[1170] 4. Compound Preparation
[1171] 4.1 Dilute the 20 mM compound stock solution with the extracellular solution. Take 5 μL of the 20 mM compound stock solution and add it to 2495 μL of the extracellular solution, dilute 500 times to 40 μM, and then perform 3-fold serial dilutions in the extracellular solution containing 0.2% DMSO to obtain the final concentration to be tested.
[1172] 4.2 The highest tested concentration was 40 μM, and there were 6 concentrations in total, namely 40, 13.33, 4.44, 1.48, 0.49, and 0.16 μM.
[1173] 4.3 The DMSO content in the final test concentration does not exceed 0.2%. This concentration of DMSO has no effect on the hERG potassium channel.
[1174] 5. Data Analysis
[1175] The experimental data were analyzed by XLFit software.
[1176] 6. Quality Control
[1177] Environment: Humidity 20-50%, temperature 22-25℃
[1178] Reagents: All experimental reagents were purchased from Sigma, with a purity of >98%
[1179] The experimental data in the report must meet the following standards:
[1180] Whole cell sealing impedance>100MΩ
[1181] Tail current amplitude>400pA
[1182] Pharmacological parameters:
[1183] The inhibitory effects of Cisapride at different concentrations on hERG channels were set as positive controls.
[1184] 7. Experimental results:
[1185] Table 9: Inhibition results of hERG current by the example compounds at various concentrations hERG results
[1186]
[1187] 8. Experimental conclusion:
[1188] The inhibition of the cardiac hERG potassium ion channel by drugs is the main cause of drug-induced QT prolongation syndrome. From the experimental results, it can be seen that the compounds of the embodiments of the present invention have no obvious inhibitory effect on the cardiac hERG potassium ion channel, and can avoid cardiac toxic side effects at high doses.
[1189] Test Example 9: Taste sensitivity test of BALB / c mice
[1190] 1. Experimental purpose:
[1191] This experiment screened out compounds with less toxic side effects on animal taste through the quinine bitter water experiment.
[1192] 2. Main instruments and materials
[1193] 2.1 Instruments:
[1194] 1. Clean bench (CJ-2F, Suzhou Fengshi Experimental Animal Equipment Co., Ltd.);
[1195] 2. Electronic balance (CPA2202D, Sartorius);
[1196] 3. Electronic balance (BSA2202S-CW, Sartorius);
[1197] 4. Water purifier (Pacific TII, Thermo).
[1198] 2.2 Reagents:
[1199] Quinine monohydrochloride dihydrate (6119-47-7, Adamas).
[1200] 2.3 Animals:
[1201] BALB / c mice, 6-8 weeks old, were purchased from Shanghai Xipu-Bikai Experimental Animal Co., Ltd.
[1202] 3. Experimental steps:
[1203] 3.1 Animal screening
[1204] One day before the experiment, all BALB / c mice were weighed, and animals with excessively high or low body weight were eliminated.
[1205] 3.2 Grouping and water restriction
[1206] BALB / c mice were randomly divided into groups according to body weight and were deprived of water and food for 12-16 hours before administration.
[1207] 3.3 Preparation of quinine aqueous solution
[1208] Weigh an appropriate amount of quinine monohydrochloride dihydrate and prepare a 3 mmol / L quinine hydrochloride aqueous solution with ultrapure water for later use.
[1209] 3.4 Preparation of test compounds
[1210] Weigh an appropriate amount of the compound to be tested and prepare it to the target concentration using the corresponding solvent according to the experimental design for later use. 3.5 Drug administration and animal quinine drinking test
[1211] Drug administration and fasting: On the day of the experiment, the animals were weighed, fasted, and the bedding was changed, and the drugs were administered according to the experimental design.
[1212] Quinine water intake test:
[1213] 1. Rinse the corresponding clean mouse drinking bottle 2-3 times with ultrapure water and prepared 3mmol / L quinine hydrochloride aqueous solution, then fill it up, weigh it and record the weight as Wi0.
[1214] 2. According to the experimental design, after a certain period of drug administration, gently place the filled water bottle on the corresponding mouse cage and start timing. After 30 minutes, gently take out the water bottle, weigh it and record the weight as Wi 30 .
[1215] 3. Calculation of water intake for each group of animals: ΔWW (g) = Wi 30 -Wi0; Calculation of water intake of a single mouse: ΔpWW (g) = ΔWW / N, where N is the number of animals in each group.
[1216] 4. Taste disturbance ratio = (drinking water with quinine hydrochloride aqueous solution and given the test drug group ΔpWW - drinking water with quinine hydrochloride aqueous solution and given the solvent control group ΔpWW) / (drinking water with ultrapure water and given the solvent control group ΔpWW - drinking water with quinine hydrochloride aqueous solution and given the solvent control group ΔpWW) × 100%. Data processing was performed using Excel or other software.
[1217] 5. Euthanize the animals after the experiment.
[1218] 4. Test results:
[1219] Table 10 Taste results of example compounds
[1220]
[1221] 5. Experimental conclusion:
[1222] From the above results, it can be seen that the compound of this patent has less toxic side effects on the taste of mice. Test Example 10: Study on the efficacy of citric acid-induced acute cough in guinea pigs
[1223] 1. Purpose of the experiment
[1224] The purpose of this study was to evaluate the efficacy of the compounds in the citric acid-induced acute cough model in guinea pigs.
[1225] 2. Experimental instruments and reagents
[1226] 2.1 Key instruments
[1227]
[1228] 2.2 Key Reagents
[1229]
[1230]
[1231] 3. Experimental operation and data processing:
[1232] 3.1 Animals
[1233] Male guinea pigs (Hartley Guinea Pig) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.
[1234] 3.2 Experimental Procedure
[1235] After adaptive feeding and reaching the target body weight (300-400 g), the animals were serially numbered and randomly grouped according to their body weight.
[1236] Cough induction method: First, place the guinea pig in the whole body volume scanning box to adapt for 3-5 minutes, then perform ATP nebulization for 2 minutes, 3 minutes interval, and then give citric acid nebulization for 5 minutes. From the beginning of citric acid nebulization, record the number of coughs and cough latency of the animal within 10 minutes.
[1237] 3.3 Dosage regimen and cough index monitoring The test compound was administered to guinea pigs by single oral gavage 2 hours before citric acid aerosolization, and placed in the respiratory plethysmography chamber of the DSI Buxco whole body plethysmography detection system (WBP) at a predetermined time for citric acid aerosolization to induce cough. From the start of citric acid aerosolization, the WBP system recorded the total number of coughs (CCnt) and cough latency (CIP) of guinea pigs within 10 minutes.
[1238] 3.4 Data Processing
[1239] All data were entered into an Excel document and expressed as mean ± standard error. One-way ANOVA was used to analyze and compare the data of each group. Statistical analysis results were considered to be significantly different when p < 0.05. The t-test method was used to compare the differences between the two groups.
[1240] The results showed that the compounds of the embodiments of the present invention could effectively improve the cough symptoms in the citric acid-induced acute cough model of guinea pigs, and the total number of coughs decreased by more than 59%.
Claims
1. A compound represented by general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof: in: L1 is selected from a bond, -(CH2) n1 -、-(CH2) n1 O(CR aa R bb ) n2 -、-(CH2) n1 S(CR aa R bb ) n2 -、-(CH2) n1 C(O)-、-(CH2) n1 NR aa -、-(CH2) n1 S(O) n2 -、-(CH2) n1 C(O)NR aa -、-C(O)NR aa (CH2) n2 -or-(CH2) n1 NR aa C(O)-, preferably a bond, -NH-, -C(O)NHCH2- or -C(O)N(CH3)CH2-; R aa or R bb Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl; Or, R aa or R bb Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; L2 is selected from -(CH2) n3 -、-(CH2) n3 O-, -(CH2) n3 S-, -(CH2) n3 NR dd -、-(CH2) n3 C(O)NR dd -or-(CH2) n3 NR dd C(O)-, preferably -CH2C(O)NH-; R dd Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; Ring A is selected from C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; preferably C 6-10 Aryl or 5-10 membered heteroaryl, preferably C 6-10 Aryl or 5-10 membered heteroaryl, more preferably phenyl, oxadiazolyl or pyridyl; R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl or 5-14 membered heteroaryloxy, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 Aryloxy, 5-14 membered heteroaryl and 5-14 membered heteroaryloxy, optionally substituted by deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl, 5-14 membered heteroaryloxy, -(CH2) m1 OR a 、-(CH2) m1 SR a 、-(CH2) m1 C(O)R a 、-(CH2) m1 NR a R b 、-(CH2) m1 C(O)NR a R b 、-(CH2) m1 NR a C(O)R b and -(CH2) m1 S(O) m2 R a is substituted by one or more substituents; R a and R b Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl; Or, R a and R b Link Form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; Ring B is: M1, M2, M3 and M4 are each independently selected from -CR A1 -、-C(O)-、-N-、-CR A1 R A2 -or-NR A3 -; R A1 ~R A3 Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Alternatively, Ring B is: M6, M7 and M8 are each independently selected from -CR A4 -, -C(O)-, -N-, -O-, -S-, -CR A4 R A5 -or-NR A6 -; R A4 ~R A6 Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl; R a Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R gg 、-(CH2) n5 OR gg 、-(CH2) n5 C(O)OR gg 、-(CH2) n5 SR gg 、-(CH2) n5 NR gg C(O)(CH2) n6 R hh 、-(CH2) n5 NR gg C(O)OR hh 、-(CH2) n5 NR gg C(O)NR hh R ii 、-(CH2) n5 NR gg R hh 、-NR gg (CH2) n5 R hh 、-(CH2) n5 C(O)NR gg (CH2) n6 R hh 、-(CH2) n5 C(O)R gg or -OC(R gg R hh ) n5 (CH2) n6 R ii ; R gg ~R ii Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl; Or, R gg ~R ii Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; x is an integer from 0 to 6; e is an integer from 0 to 6; n1, n3, and n5 are each independently an integer from 0 to 3; n2 and n6 are each independently an integer from 0 to 2; m1 is an integer from 0 to 3; and m2 is an integer from 0 to 2.
2. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, the C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl, 5-8 membered heteroaryl, -(CH2) m1 C(O)R a 、-(CH2) m1 NR a R b 、-(CH2) m1 C(O)NR a R b 、-(CH2) m1 NR a C(O)R b and -(CH2) m1 S(O) m2 R a In one or more substituents, R1 is preferably hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, trifluoromethyl, fluorine, chlorine, bromine, amino, isopropenyl, cyclopropyl, cyclopentyl, cyclopentenyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, phenyl, pyridinyl, R a and R b Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; Or, R a and R b Link Form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl; m1 is an integer from 0 to 3; and m2 is an integer from 0 to 2.
3. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S; More preferably, hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy , fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
4. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Preferred are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S; More preferably, hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy , fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
5. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R a is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 The invention further comprises an aryl group or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, more preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl yl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ... R gg ~R ii Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; Or, R gg ~R ii Any two links in C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; n5 is an integer from 0 to 3; and n6 is an integer from 0 to 2.
6. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: M1, M2, M3 and M4 are each independently CR A1 ; R A1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl , methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
7. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: At least one of M1, M2, M3 and M4 is N, preferably, M4 is N, and M1, M2 and M3 are each independently selected from CR A1 ; Alternatively, M1 is N, and M2, M3 and M4 are each independently selected from CR A1 ; R A1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl , methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
8. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring A is selected from M5 is selected from -N- or -CR4-, preferably -N- or -CH-; R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 The aryl and 5-12 membered heteroaryl are substituted by one or more substituents, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, more preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 The aryl group or the 5-10 membered heteroaryl group containing 1-3 N, O or S atoms is further preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl yl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ...
9. The compound according to any one of claims 1 to 8, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound is further represented by general formula (II): Here, e is an integer from 0 to 3.
10. The compound according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound is further represented by general formula (III): in: R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, more preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 The aryl group or the 5-10 membered heteroaryl group containing 1-3 N, O or S atoms is further preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl yl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, glycid ... R b is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, more preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, thio, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy yl, cyclohexyl, cycloheptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooxypropyl, cyclobutyl, cyclooxypentyl, cyclohexyl, cycloheptyl, aziridine, azetidinyl, azetyl, azepanyl, azepanyl, thienyl, pyrrolyl, pyridyl, pyranyl, piperazinyl, phenyl, or naphthyl; and y is an integer from 0 to 3.
11. The compound according to claim 10, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound is further represented by general formula (IV): in: Ring C is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered hetero or absent, preferably C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, more preferably C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, further preferably cyclopropyl, cyclopentyl, cyclopentenyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, phenyl or pyridinyl; R c is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 aryloxy, 5-14 membered heteroaryl, 5-14 membered heteroaryloxy, -(CH2) m3 OR c 、-(CH2) m3 SR c 、-(CH2) m3 C(O)R c 、-(CH2) m3 NR c R d 、-(CH2) m3 C(O)NR c R d 、-(CH2) m3 NR c C(O)R d or -(CH2) m3 S(O) m4 R c , the amino group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 Aryloxy, 5-14 membered heteroaryl and 5-14 membered heteroaryloxy, optionally substituted by deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, C 6-14 The aryloxy, 5-14 membered heteroaryl and 5-14 membered heteroaryloxy are substituted by one or more substituents, preferably hydrogen, halogen, amino, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl, 5-8 membered heteroaryl, -(CH2) m3 OR c 、-(CH2) m3 SR c 、-(CH2) m3 C(O)R c 、-(CH2) m3 NR c R d 、-(CH2) m3 C(O)NR c R d or -(CH2) m3 NR c C(O)R d , the amino group, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, optionally substituted by deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 The aryl group and the 5-8 membered heteroaryl group are substituted by one or more substituents, and further preferably hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, trifluoromethyl, fluorine, chlorine, bromine, amino or -C(O)CHF2; R c and R d Each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl; Or, R c and R d Link Form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents selected from aryl and 5-14 membered heteroaryl; m3 is an integer from 0 to 3; m4 is an integer from 0 to 2; and z is an integer from 0 to 6.
12. The compound according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound is further represented by general formula (V): in: R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted by deuterium, halogen, amino, hydroxy, cyano, nitro, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl and 5-12 membered heteroaryl are substituted with one or more substituents; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally substituted by deuterium, halogen, amino, hydroxy, cyano, nitro, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by one or more substituents of aryl and 5-12 membered heteroaryl; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-8 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl; and e is an integer from 0 to 3.
13. The compound according to claim 12, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally substituted with deuterium, halogen, amino, hydroxy, cyano, nitro, oxo, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 The aryl group and the 5-10 membered heteroaryl group are substituted by one or more substituents, preferably the following groups: -H、-NH2、-F、-Cl、-Br、-CH3、-CH2CH3、-CF3、 R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably hydrogen, amino, cyano, fluorine, chlorine, bromine, methyl, isopropyl, trifluoromethyl, methoxy, cyclopropyl or morpholinyl; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-1. membered heteroaryl, preferably hydrogen or cyano; and e is an integer from 0 to 3.
14. The compound according to any one of claims 1 to 13, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The specific structure of the compound is as follows:
15. A pharmaceutical composition comprising a therapeutically effective dose of a compound according to any one of claims 1 to 14, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.
16. Use of the compound according to any one of claims 1 to 14, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 15 in the preparation of a P2X3 inhibitor drug.
17. Use of the compound according to any one of claims 1 to 14, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 15 in the treatment of neurogenic diseases; preferably, the neurogenic disease is selected from gynecological diseases, urinary tract disease states, respiratory disorders or pain-related diseases or conditions, more preferably endometriosis, overactive bladder, pulmonary fibrosis or chronic cough.
18. The use according to claim 17, wherein the pain-related disease or condition is selected from neuropathic pain or pain or discomfort associated with uterine fibroids.
